Protocol Amendment 3  ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa  Alexion Pharmaceuticals, Inc.  
Alexion Confidential 01 December 2022  Page 1 A RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA IN ACUTE 
INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL 
FACTOR  XA INHIBITOR  
DRUG NA ME: Andexanet Alfa  
PROTOCOL  NUMBER: 18-513
PHASE: 4
IND:  015089
NCT NUMBER:  03661528
EudraCT NUMBER:  2018 -002620 -17
TRIAL  SPONSOR: Alexion Pharmaceuticals, Inc.  
121 Seaport Blvd.  
Boston, MA 02210  
MEDICAL  MONITOR:  
 
Alexion Pharmaceuticals UK Ltd.  
Phone:   
Email:   
PROTOCOL  DATE: Original:  
Netherlands v0.1:  
Switzerland v0.2:  
Amendment 1:  
Switzerland v1.1:  
Amendment 2:  
United States v2.1:  
Switzerland v2.2:  
Russia v2.3:  
Amendment  3: 02 July 2018  
21 March 2019  
13 January 2020 
15 April 2020  
13 May 2020  
29 July 2021  
02 September 2021  
18 November 2021  
31 January 2022  
01 December  2022 
 
CONFIDENTIALITY STATEMENT  
This protocol is the property of Alexion  Pharma ceuticals, Inc.  It is a  conf idential co mmunication.  Accep tance 
implies an agreement not t o discl ose in formation con tained herein  that is not otherwise publicly available, with t he 
excep tion that it may be discl osed to an Institutional Review Board (IRB)/Independe nt Ethics Commi ttee ( IEC)  for 
the purpose o f obtaining  approval to conduct  the study.  The  IRB /IEC is requested and expec ted to main tain 
confidentia lity.  This  docume nt may not be used or published witho ut the consent  of Alexion  Pharma ceuticals, Inc. NCT #: [STUDY_ID_REMOVED]

Protocol Amendment 3  ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa  Alexion Pharmaceuticals, Inc.  
Alexion Confidential 01 December 2022  Page 2 INVESTIGA TOR’S AGR EEMENT 
I have read ALXN2070 Study18 -513 Pro tocol Amendment 3 (dated 01 December  2022) entitl ed, 
“A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients 
Receiving an Oral Factor Xa Inhibitor,”  and agree to abide by al l provisions set forth therein.  
I agree to conduct the study in accordance with all applicable government regulations, the 
principles of the International Council on Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) E6 Guidelines for Good Clinical Practice (GCP), and the 
principles of the World Medical Association Declaration of Helsinki.  
I agree to ensu re that the confi dential informa tion contained in thi s docu ment will not be used 
for any pu rpose o ther than the eval uation or conduct o f the c linical investigation w ithout the 
prior wr itten consent of Alexion  Pharmaceuticals, Inc. 
Signature of Principal Investigator  
Name of Principal Investigator (Print)  Date (DD Month YYYY)  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 3 SPONSOR’S AGREEMENT  
I have read ALXN2070 Study18 -513 Protocol Amendment 3 (dated 01 December  2022) entitled 
“A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients 
Receiving an Oral Factor Xa Inhibitor,”  and agree to abide by all provisions  set forth therein.  
I agree to conduct the study in accordance with all applicable government regulations, the 
principles of the ICH E6 Guidelines for GCP, and the principles of the World Medical 
Association Declaration of Helsinki.  
  
  
 
  
  
Alexion Pharmaceuticals UK Ltd   Date (DD Month YYYY)  
 

Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 4 TABLE OF  CON TENTS 
Page 
INVESTIGA TOR’S AGR EEMENT ......................................................................................................... 2  
SPONSOR’S AGREEMENT  ..................................................................................................................... 3  
TABLE OF CON TENTS ....................................................................................................................... 4  
LIST OF TABLES ................................................................................................................................. 7  
LIST OF FIGURES  ................................................................................................................................ 7  
OVERVIEW OF CHANGES IN THE CURRENT AND PREVIOUS PROTOCOL 
AMENDMENTS  ............................................................................................................................ 8  
PROTOCOL  SYNO PSIS ......................................................................................................................... 16 
LIST OF A BBREVIATIO NS AND TERMS ......................................................................................... 24 
1.0 INTRODUCTION  ....................................................................................................................... 26 
2.0 STUDY OBJECTIVES  ................................................................................................................ 28 
3.0 INVESTIGATIONAL PLAN  ..................................................................................................... 30 
3.1. OVER ALL STUDY DE SIGN AND PLAN:   DESCRIPTION ................................................ 30 
3.2. BLINDING AND RANDOMIZATION .................................................................................. 33 
3.2.1.  Randomization  ................................................................................................................. 33 
3.2.2.  Blinding  ........................................................................................................................... 34 
3.3. DURAT ION OF  STUDY ......................................................................................................... 34 
3.3.1.  Study Population  ............................................................................................................. 34 
3.3.2.  Rationale for the Key Efficacy Endpoints  ....................................................................... 35 
3.3.3.  Rationale for the Dose Regimen of Andexanet  ............................................................... 37 
3.4. SAFETY PLAN AND MONITORING ................................................................................... 37 
3.5. BENEFIT AND RISK ASSESSME NT .................................................................................... 38 
3.5.1.  COVID-19 ....................................................................................................................... 39 
4.0 SELECTIO N OF STUDY  POPULATIO N AN D CRITE RIA FOR W ITHDRAWAL  ......... 40 
4.1. INCLUSION CRITER IA ......................................................................................................... 40 
4.2. E
XCLUSION CRITERIA  ........................................................................................................ 41 
4.3. CRITERIA F OR DISCONTINUATION FROM THE STUDY  .............................................. 42 
4.4. CRITERIA F OR DISCONTINUATION OF ANDEXANET  .................................................. 42 
4.5. PATIENT RE PLA CEMENT .................................................................................................... 43 
4.6. STUDY COMPLETION  .......................................................................................................... 43 
4.7. END OF THE TRIAL .............................................................................................................. 43 
5.0 ENRO LLME NT AND STUDY P ROC EDURES ...................................................................... 44 
5.1. VISI T PROCEDU RES (DAYS 1 TO 30 –37) .......................................................................... 44 
5.1.1.  Screening and Enrollment  ............................................................................................... 44 
5.2. UNSCHE DUL ED VISIT .......................................................................................................... 44 
5.3. EAR LY TERMINAT ION VISIT ............................................................................................. 44 
6.0 DRUG SUPPLIES AND DOSING  ............................................................................................... 46 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 5 6.1. FORMULATION  ...................................................................................................................... 46 
6.2. DOSING AND ADMINISTRATION  ...................................................................................... 46 
6.3. STORAGE  ................................................................................................................................ 47 
6.4. DRUG ACC OUNTABILIT Y AND COM PLIAN CE .............................................................. 47 
7.0 PRIOR AND CONCOMIT ANT  MEDICATIO NS AND TREATMENTS ............................ 48 
7.1. PRIO R ME DICATION S AND TREATMEN TS ..................................................................... 48 
7.2. CONCOMITANT MEDICATION S, HEMOSTATIC, AND PRO -COAGULANT 
TREATMENTS ........................................................................................................................ 48 
7.2.1.  Anticoagulants and Antiplatelet Drugs  ............................................................................ 49 
7.2.2.  Blood Products  ................................................................................................................ 50 
7.2.3.  Procoagulant Blood Products  .......................................................................................... 50 
7.2.4.  Hemostatic Agents ........................................................................................................... 50 
7.3. DIAGNOSTIC AND THERAPEUTIC PROCEDURES FOR BLEEDING  ........................... 51 
7.4. CONTINUED BLEEDING, RE -BLEEDING, AND RESCUE THERAPY  ........................... 52 
7.5. INFUSION REACTIONS  ........................................................................................................ 52 
7.6. THROMBOTIC EVENTS  ........................................................................................................ 53 
8.0 ADVERSE EVE NT REPORTING ............................................................................................ 54 
8.1. ADVERSE EVENT DEF INITIONS ........................................................................................ 54 
8.1.1.  Study -specific Exceptions to Adverse Event/Serious Adverse Event Reporting  ............ 55 
8.2. SERIOUS ADVER SE EVENT DEFINITION ......................................................................... 55 
8.2.1.  Regulatory Reporting Requirements for Serious Adverse Events  ...................................  56 
8.
3. SUSPECTED UNEXPECTED SERIOUS ADVERSE REACTIONS  .................................... 57 
8.4. ADVERSE EVENTS OF SPEC IAL I NTEREST .................................................................... 57 
8.5. ASSESSMENT OF CAU SAL RELATIONS HIP .................................................................... 57 
8.6. ASSESSMENT OF SEV ERITY .............................................................................................. 58 
8.7. ADVERSE EVENT REPORTING  .......................................................................................... 59 
8.8. REPORT ING OF  SERIOUS ADVERSE E VENTS A ND AD VERSE E VENTS OF 
SPEC IAL I NTEREST .............................................................................................................. 59 
8.9. CONTRACEPTION .................................................................................................................. 60 
8.9.1.  Pregnancy Reporting  ....................................................................................................... 61 
9.0 STUDY ASSE SSMENTS ............................................................................................................ 62 
9.1. EFFI CACY ASSESSMEN TS .................................................................................................. 62 
9.1.1.  Effective Hemostasis  ....................................................................................................... 62 
9.1.2.  Anti-f Xa Act ivity ............................................................................................................ 62 
9.1.3.  Thrombin Generation ...................................................................................................... 62 
9.1.4. Glasgow Coma Scale (GCS) Score  ................................................................................. 62 
9.1.5.  Modified Rankin Scale  .................................................................................................... 63 
9.1.6.  EQ-5D (EuroQol -5 Dimension)  ...................................................................................... 63 
9.2. SAFETY ASSESSME NTS (OTHER TH AN ADV ERSE EVENTS) ...................................... 63 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 6 9.2.1.  Vital Signs, Height, and Weight ...................................................................................... 63 
9.2.2.  Clinical Laborator y Testing ............................................................................................. 63 
10.0  STATIST ICAL  CONSIDE RATIO NS AND DAT A ANALYS IS ............................................ 65 
10.1.  GENERAL CONS IDERATIONS ............................................................................................ 65 
10.2.  RANDOMI ZAT ION ................................................................................................................ 65 
10.3.  DETERMINATION OF SAMPLE SIZE ................................................................................. 65 
10.4.  ANALYSIS POPULAT IONS  .................................................................................................. 66 
10.4.1.  Safety Anal ysis Population .............................................................................................. 66 
10.4.2.  Efficac y Anal ysis Populati on .......................................................................................... 67 
10.4.3.  Patient Disposition  ........................................................................................................... 67 
10.4.4.  Baseline and Demographic Characteristics  ..................................................................... 67 
10.4.5.  Treatment Compliance  .................................................................................................... 67 
10.5.  EFFICACY ENDPOINTS AND ANALYSES  ........................................................................ 67 
10.5.1.  Population  ........................................................................................................................ 67 
10.5.2.  Definitions  ....................................................................................................................... 67 
10.5.3.  Efficacy Endpoints  .......................................................................................................... 68 
10.5.4.  Statistical Methodology for Efficacy Endpoint Analyses ................................................ 70 
10.6.  SAFETY ENDPOINTS AND SUMMARIES .......................................................................... 72 
10.6.1.  Adverse Events  ................................................................................................................ 72 
10.6.2.  Thrombotic Events  .......................................................................................................... 73 
10.6.3.  Deaths  .............................................................................................................................. 73 
10.6.4.  Invasi ve Procedures ......................................................................................................... 73 
10.6.5.  Hospitalizations ............................................................................................................... 73 
10.6.6.  Laborator y P
arameters ..................................................................................................... 74 
10.6.7.  Vital Signs  ....................................................................................................................... 74 
10.7.  INTERIM ANALYSES  ............................................................................................................ 74 
10.7.1.  Stopping Criterion Due to Efficacy at Interim ................................................................ 74 
10.7.2.  Sample Size Re-estimation at Interim  ............................................................................. 74 
10.7.3.  Primary Analysis if Study is Continued from Inte rim ..................................................... 75 
10.8.  SUBGROUP ANALYSES  ....................................................................................................... 75 
11.0  STUDY COMMITTEES AND COMMUNICATIONS  ........................................................... 76 
12.0  INVESTIGA TOR AND ADM INIST RAT IVE R EQUIREMENTS ........................................ 77 
12.1.  INSTITUTIONAL REVIEW BOARD OR INDEPE NDENT E THICS COMMITTEE .......... 77 
12.2.  INFORMED CONSE NT .......................................................................................................... 77 
12.3.  SUPPLEMENTA RY DOC UMENTAT ION ............................................................................ 78 
12.4.  DAT A COLLECTION AND MANAGEMENT RESPONSIBILITIES  .................................. 79 
12.5.  STUDY RECORDS RETENTION  .......................................................................................... 79 
12.6.  DEVIATI ON FROM THE PROTOCOL  ................................................................................. 79 
12.7.  DISCLOSURE OF DATA  ........................................................................................................ 80 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 7 12.8.  DRUG ACCOUNTABILITY ................................................................................................... 80 
12.9.  STUDY MONITOR ING .......................................................................................................... 80 
13.0  REFERE NCES .............................................................................................................................. 82 
14.0  LIST OF APPENDICES  ................................................................................................................ 85 
APPENDIX A. SCHEDULE OF ACTIVITIES .............................................................................. 86 
APPENDIX B.  ADJUDICATION CRITERIA FOR HEMOSTATIC EFFICACY  ....................... 90 
APPENDIX C.  GLASGOW COMA SCALE (GCS)  ...................................................................... 91 
APPENDIX D. MODIFIED RANKIN SCALE (MRS)  .................................................................. 92 
APPENDIX E. NATIONAL INSTITUTES OF HEALTH STROKE SCALE ............................... 93 
APPENDIX F. COVID-19:  POTENTIAL RISKS AND MITIGATION MEASURES  .............. 101 
APPENDIX G. EXAMPLES OF PLANNED MINIMALLY INVASIVE SURGERIES/ 
PROCEDURES ALLOWED ....................................................................................................... 102 
APPENDIX H. DISSEMINATED INTRAVASCULAR COAGULATION SCORING 
ALGORITHM  ............................................................................................................................. 103 
APPENDIX I.  DEFINITIONS OF CARDIOGENIC SHOCK, SEVERE SEPSIS AND 
SEPTIC SHOCK  .......................................................................................................................... 104 
APPENDIX J. DEFINITION OF FEMALE OF CHILDBEARING POTENTIAL  .................... 105 
APPENDIX K. GUIDANCE FOR SUBMISSION OF POTENTIAL THROMBOTIC 
EVENTS FOR ADJUDICATION  ............................................................................................... 106 
APPENDIX L. EUROQOL -5 DIMENSION (EQ-5D) QUESTIONNAIRE  ................................ 109 
 
List of Tables  
Table  1: Study 18-513: Objectives and Endpoints  ............................................................................... 28 
Table  2: Reconstitution Volumes and Composition for Andexanet  ..................................................... 46 
Table  3: Dosing Paradigm for Andexanet  ............................................................................................ 46 
Table  4: Andexanet Dose Regimens  .................................................................................................... 47 
Table  5: Allowed Use of Concomitant Medications and Treatments .................................................. 48 
 
List of Figures  
Figure  1: Events Through the First 12 Hours After Enrollment  ............................................................ 31 
 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 8 OVERVIEW OF CHANGES IN THE CURRENT AND PREVIOUS PROTOCOL 
AMENDMENTS  
Substantial changes to the protocol in the current and previous amendments are summarized 
below. 
Protocol Version and 
Date  Substantial Changes  
Original Netherlands  
21 March 2019  • Added Summary of Changes table to highlight document revisions  
• Modified Inclusion Criteria #1 to allow for ‘deferred consent’ procedure as 
allowed in emergency situations in the Netherlands.  Deferred consent is 
consistent with the principles of emergency consent (defined as consent from a 
qualified medical professional) as described in Section 13.2 of the protocol.  
• In cases of deferred consent, the tim e of study physician’s documented decision 
to include the patient into the study will serve as “time of consent” with respect to protocol -specific procedures.  
• In all cases where the patient does not sign informed consent form (ICF) prior to study entry, informed consent will be obtained as soon as realistically 
possible after inclusion in the trial and in accordance with the Declaration of 
Helsinki, ICH GCP, the Data Protection Directive (Directive 95/46/EC) and national and local regulations.
 
Original Sw itzerland:  
13 January 2020  • Added Summary of Changes table to highlight document revisions  
• Added Inclusion Criteria #7 to specify required contraceptive methods  
• Added description of randomization code safekeeping  
• Added rationale for inclusion of vulnerabl e patients  
• Added reasons for discontinuation from the study  
• Added country specific requirements for reporting of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) in Switzerland  
• Added reporting timelines for termination, interruption and completion of the trial  
• Added consenting requirements for patients who were initially incapacitated but regained their decision -making capacity  
• Added clarification about ICH E6 R2 EDC conformity  
• Added information about data management of patients who refuse to participate 
after inclusion in the trial based on legal representative or medical proxy 
consent  
• Central laboratories specified  
Protocol Amendment 1  
15 April 2020 
 Updated eligibility criteria as follows:  
• Reworded Inclusion Criterion #1 for clarity  and to allow for ‘deferred consent’ 
procedure.  Deferred consent is consistent with the principles of emergency 
consent (defined as consent from a qualified medical professional) as described 
in Section 13.2 of the protocol.  
In cases of deferred consent, the time of study physician’s documented decision to 
include the patient into the study will serve as “time of consent” with respect to 
protocol -specific procedures.  
• In all cases where the patient does not sign ICF prior to study entry, informed 
consent will be obtained as soon as realistically possible after inclusion in the trial and in accordance with the Declaration of Helsinki, ICH GCP, the Data Protection Directive (Directive  95/46/EC) and national and local regulations.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 9 Protocol Version and 
Date  Substantial Changes  
• Updated Inclusion Criterion #2 to specify a maximum age (90 years old) for 
study eligibility  
• Modified Inclusion Criterion #3 to limit enrollment to patients with 
intracerebral hemorrhage to increase the homogeneity of the study population 
and to clarify eligible hematoma blood volume.  
• Reworded Inclusion Criterion #5 to exclude low dose Factor Xa (FXa) 
inhibitors, to clarify a scenario in which patients who received their last dose of 
oral FXa inhibitor >1 5 hours prior to randomization (or whose time since the 
last oral FXa inhibitor dose is unknown) may still be eligible for enrollment  
• Updated Inclusion Criterion #6 to decrease maximum time from bleeding 
symptoms onset to baseline imaging scan from 12 hour s to 6 hours.  
• Added Inclusion Criterion #7 to provide contraception requirements, and added 
guidance for women of childbearing potential and men with sexual partners of 
childbearing potential 
• Added Inclusion Criterion #8 to ensure that pregnant women are not enrolled  
• Updated Exclusion Criterion #1 to clarify that minimally invasive surgery/procedures are allowed if they are not expected to signi ficantly affect 
hematoma volume  
• Removed the original Exclusion Criterion #3 for intracerebral hematoma 
volume > 60 mL and instead included required bleed volume in Inclusion 
Criterion #3 (replaced Exclusion Criterion #3 with “Purposefully left blank”).
  
• Modified Exclusion Criterion #6 for additional clarity with respect to expected survival  
• Added Exclusion Criterion # 14 to exclude any patients with tumor -related 
bleeding  
• Added Exclusion Criterion #15 to exclude patients with a known hypersensitivity to any component of andexanet alfa (andexanet)  
• Added Exclusion Criterion #16 to exclude any patient with a baseline National Institutes of Health Stroke Scale (NIHSS) >35 at the time of consent  
• Added language to allow standard of care laboratory assessments or procedures 
performed at acute illness, but before signing of informed consent, to be used 
for assessing eligibility  
Update d objectives, endpoints, analyses, and study design as follows:  
• Added a secondary efficacy objective to evaluate the effect of andexanet versus usual care on neurologic function  
• Deleted the additional efficacy objective to evaluate the effect of ande xanet 
versus usual care on clinical and functional neurologic status  
• Added an additional efficacy objective to evaluate the occurrence and outcome of extracranial bleeding  
• Added an additional efficacy objective to evaluate the effect of andexanet versus us ual care on health -related quality of life  
• Added a safety objective to evaluate the occurrence of invasive intracranial procedures post -randomization 
• Updated the primary endpoint to clarify criteria required for a patient to be considered as having excelle nt or good hemostatic efficacy  
• Reworded the first secondary efficacy endpoint to percent change and added timing details  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 10 Protocol Version and 
Date  Substantial Changes  
• Added a secondary efficacy endpoint for the Glasgow Coma Scale (GCS) at 24 
hours  
• Added a secondary efficacy endpoint for neurologic det erioration  
• Added an additional efficacy endpoint for the utility -weighted modified Rankin 
Scale (uw -mRS)  
• Updated the additional efficacy endpoint for NIHSS to include assessments at 
2, 3, 6, and 72 hours  
• Updated the additional efficacy endpoint for GCS to include assessments at 2, 3, 6, and 72 hours  
• Added an additional efficacy endpoint of number of patients with a ≥ 7 -point 
increase from baseline in NIHSS at 12 hours post- randomization  
• Added an additional efficacy endpoint of number of patients receiving rescue therapy between 3- and 12 -hours post -randomization  
• Updated the additional efficacy endpoin t of occurrence and outcome of non-
ICH bleeding to occurrence and outcome of extracranial bleeding  
• Added an additional efficacy endpoint of the EuroQol -5 Dimension (EQ- 5D) 
Questionnaire  
• Added a definition of bleeding mortality to the associated safety endp oint 
• Added a safety endpoint to assess the number of patients with invasive intracranial procedures performed post -randomization to manage the 
intracranial hematoma and/or its complications  
• Provided more detail around the re -hospitalization safety endpoint  
• Deleted the safety endpoint of clinically relevant changes in vital signs  
• Updated the analysis of the primary endpoint and removed some details that will instead be provided in the Statistical Analysis Plan (SAP)  
• Updated the analyses for the secondary end points  
• Updated the analyses for the additional efficacy endpoints  
• Added subgroup analyses based on usual care therapy received for those 
patients randomized to that treatment group and time since last FXa inhibitor 
dose, and removed subgroup analysis based on primary compartment of 
bleeding  
• Updated details on summaries to be generated to describe safety endpoints to reflect changes to safety endpoints  
• Updated details regarded the planned analysis of deaths  
• Added a section to describe the planned analysis on  invasive procedures  
• Added details regarding the planned data to be summarized for hospitalizations  
• Updated alpha spending for the interim analysis  
• Updated definitions of efficacy analysis populations  
• Added section to clarify the population on which the primary and secondary endpoints will be analyzed  
• Updated the sample size from approximately 440 subjects to approximately 900 subjects and the number of investigational sites from approximately 100 to 
approximately 200  
• Added stratification factors of intende d-usual -care-agent and time from 
symptom onset to baseline imaging scan, and removed stratification by site, to the randomizations scheme  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 11 Protocol Version and 
Date  Substantial Changes  
• Updated the adjudication criteria for hemostatic efficacy to reflect other 
changes made to the protocol  
• Updated detail s on how missing data will be handled for the primary and 
secondary endpoints; deleted details on how missing data will be handled for 
the additional efficacy endpoints  
 
Corrections, clarifications, and further guidance were included as follows:  
• Added language to clarify that some assessments are only required at the Early 
Termination visit if they have not yet been performed during treatment  
• Added more clarity around Data Safety Monitoring Board (DSMB) roles and 
responsibilities  
• Added guidance that Investigators should consider maintaining systolic blood pressure at a target of 140 mmHg  
• Updated the study schematic to reflect changes to treatment and assessment timing  
• Updated language to require patients with a positive anti -andexanet antibody 
response a t Day 30 to be followed after the study for up to approximately 
120 days 
• Removed the requirement that andexanet be prepared prior to randomization for all patients  
• Provided guidance around the use of blood products prior to screening  
• Provided guidance aro und the use of concomitant medications, hemostatic 
agents, pro- coagulant treatments, surgical intervention, and rescue therapy 
allowed during the study 
• Updated language to differentiate between discontinuation of study drug and discontinuing from the study 
• Updated the definition of study completion  
• Added language to clarify timing for usual care dosing  
• Corrected a discrepancy that incorrectly included serious and severe infusion reactions as AESI  
• Clarified text around adverse event (AE) reporting  
• Adde d a section on hemostasis assessments and added NIHSS assessments at 
2 hours, 24 hours, and 72 hours post- randomization  
• Added a section on GCS assessments, with assessments performed at baseline and at 2, 3, 6 -, 12-, 24-, and 72 -hours post- randomization  
• Clarified that procedures that might interfere with the assessment of hemostatic 
efficacy are to be excluded  
 
Operational changes were made as follows:  
• Updated roles and responsibilities of study committees  
• Added text to allow the Day 7 visit to be conducted by phone  
• Changed 15 minute time -point to 30 minute time -point relative to IP 
administration – dosing must be within 30 minutes from Randomization and 
within 120 minutes of computed tomography (CT) scan.  
• Increased allowable timeframe to perform the 12 -hour imaging scan from 
11-13 hours to 11 -15 hours post- randomization.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 12 Protocol Version and 
Date  Substantial Changes  
• Added language to encourage completeness in data collection and to allow for 
recording of Day 30 mortality status in the clinical database even if patients 
discontinue from the study for reasons other than withdrawal of consent  
• Provided clarity around the use of an independent unblinded statistician and overall blinding  
• Added timing details for anti -fXa activity assessments to protocol body  
• Added timing details for thrombin generation assessments to protocol body  
• Changed the window for biomarker endpoints  
• Updated clinical trial data, where updated data were available 
Protocol Amendment 1.1 Switzerland  
13 May 2020 • Added Summary of Changes table to highlight document revisions  
• Added description of randomization code safekeeping  
• Added rationale for inclusion of vulnerable patients  
• Added reasons for discontinuation from the study  
• Added country ‑specific requirements for reporting of SAE s and AESI  in 
Switzerland  
• Added reporting timelines for termination, interruption, and completion of the 
trial 
• Added consenting requirements for patients who were initially incapacitated but 
regained their decision -making capacity  
• Added clarification about ICH E6 R2 EDC conformity  
• Added information about data management of patients who refuse to participate 
after inclusion in the trial based on legal representative or medical proxy consent  
• Central labs were specified  
Protocol Amendment 2  
29 July 2021  Updated eligibility criteria as follows:  
• The patient age requirement has been revised to allow those older than 90  years 
(Inclusion Criterion #2).  
• Patients with a hematoma volume of less than 0.5  mL are now excluded 
(Inclusion Criterion #3).  
• Removed “any bleeding into the epidural space” (Exclusion Criterion #4) . 
• Clarified minimum anti -fXa activity of patients treated with direct and indirect 
FXa inhibitor treatment (Inclusion Criterion #5).  
• Enoxaparin- treated patients have been added to those eligible for study 
inclusion ( Inclusion Criterion #5).  
• Clarified guidance for avoiding pregnancy (Inclusion Criterion #7).  
• Aligned Exclusion Criteria #10, #11, and #12 with the restricted prior 
medications and treatments in Section  7.1  
• Removed NIHSS score > 35 at the time of consent (Exclusion Criterion #16 of Protocol Amendment 1) and added “NIHSS score ≤  35 at the time of consent” 
(Inclusion Criterion #9).  
Updated objectives, en dpoints, analyses, and study design as follows:  
• A table (Table  1)outlining study objectives and corresponding endpoints has 
been added to the protocol body (Section  2.0); aligned endpoint descriptions in 
Synopsis,  Table  1, Section  10.5.3 and Section  10.5.4.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 13 Protocol Version and 
Date  Substantial Changes  
• The secondary efficacy objective related to  percent change from baseline to 
nadir in anti -fXa activity was changed from 3 to 2 hours  post-randomization.  
• The secondary efficacy objective related to neurologic function has been 
recategorized as an additional efficacy objective.  
• Secondary endpoints related to neurofunctional scores (NIHSS and GCS at 24 hours) have been recategorized as additional efficacy endpoints.  
• Removed “occurrence and outcome of extracranial bleeding” as an additional efficacy objective and endpoint.  
• Added procedures to the early termination visit (Section  5.3) and clarified that 
the final assessment of b leeding is to be performed if the patient withdraws 
from the study prior to the 12 -hour time point.  
• Antibodies to host cell protein will not be analyzed.  
• Added a pre -planned sample size re- estimation (SSR) (Section  10.7). 
Corrections, clarifications, and further guidance were included as follows:  
• The Introduction section has been shortened by deleting the latter subsections detailing the nonclinical and clinical experience with andexanet.  In place of 
those subsections, the reader is referred to the Investigator’s Brochure (IB), which is comprehensive and up to date.  
• Clarified that the baseline scan may be repeated only once (Inclusion Criterion #4). 
• Removed hydrocephalus from Imaging Core Laboratory assessments (Section  3.1). 
• Clarified criteria for discontinuation from the study (Section  4.3). 
• Updated reconstitution volumes and composition for andexanet (Section  6.1). 
• Clarified timing of andexanet administration relative to randomization (Section  3.1 and Section  6.2). 
• Clarified use of hemostatic agents, procoagulant blood products, and other unplanned rescue procedures and surgeries within 3 hours post randomization
 
and adjudication by Endpoint Adjudication Committee (EAC) (Section  7.2 and 
Section  10.5.3.1 ). 
• Clarified requirements for reporting of abnormal laboratory findings as AEs (Section  8.1).  
• Added study- specific exceptions to AE and SAE reporting (Section  8.1.1 ). 
• Clarified the blinded and unblinded GCS evaluation time -points (Section  9.1.4 ). 
• Clarified scope of adjudication of primary endpoint by EAC  (Section  10.5.3.1 ). 
• Updated the ANNEXA -4 study data (Section  10.3).  
• Minor clarifications and revisions throughout.  
Operational changes were made as follows:  
• The medical monitor has been changed.  
• The Sponsor identity has been updated following the acquisition of Portola by Alexion.  
• A section has been added on the potential risks to study participants posed by the coronavirus disease 2019 ( COVID -19) pandemic (Section  3.5.1).  
• A defi nition for the end of the trial (last visit, last patient) has been added 
(Section  4.7). 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 14 Protocol Version and 
Date  Substantial Changes  
• Added temperature excursion requirements (Section  6.3). 
• The AE reporting (Section  8.0) has been revised to align with Alexion Global 
Drug Safety and data standards, and all applicable regulations and guidances.  
• The definition of and reporting requirements for suspected unexpected serious 
adverse reactions (SUSARs) have been added (Section  8.3). 
• The section on contraception (Section  8.9) has been revised to specify birth 
control methods that are considered “highly effective.”  Sexual abstinence has been included in this list.  
• The section on Investigator and administrative requirements (Section  12.0) has 
been revised to align with Alexion standards.  
• The IRB/IEC has been added to those permitted to conduct trial -related 
monitoring and audits ( Section  12.9). 
• Blood pressure management has been removed from study days 7, 14, and 30 
(or ET) in the Schedule of Activities (Appendix A ). 
• An intracerebral hemorrhage -related diagnostic and therapeutic procedure was 
added at the Day 30/Early Termination visit (Appendix A ). 
• The sepsis definition was updated (Appendix I ). 
Protocol Amendment 
2.1 United States  
02 September 2021  Revised Inclusion Criterion  #1 (Synopsis and Section  4.1) Section  12.2 (Informed 
Consent), and the Schedule of Activities ( Appendix A ) to remove deferred consent 
as an option for study entry.  
Protocol Amendment 2.2 Switzerland  
18 November 2021 All changes described above for Protocol Amendment 2 dated 29 July 2021 were 
incorporated into this amendment. The Switzerland -specific changes implemented in 
Protocol Amendment 1.1 Switzerland, dated 13 May 2020, have been maintained.  
Protocol Amendment 
2.3 Russia  
31 January 2022 Added Appendix M for clinical trial sites in Russia (Enrollment of Patients Who 
Cannot Provide Their Own Consent); and added references to Appendix M to the 
protocol synopsis (Inclusion Criterion #1), Section  3.1 (Overall Study Design and 
Plan), Section  3.3 (Duration of Study), Section  4.1 (Inclusion Criterion #1), 
Section  5.1.1 (Screening and Enrollment), Section 12.2 (Informed Consent), 
Section  14.0 (List of Appendices), and Appendix  A (Schedule of Activities).  
Protocol Amendment 3  
dd Month 2022 • Updated efficacy objectives and endpoints to include timepoints that were omitted in error in the Synopsis, Table 1, and Section 10.5.3.3.  
• Clarified  interim analys is stopping criteria based on primary efficacy endpoint.  
• Deleted “or > 0.5 IU/mL for enoxaparin” from “If a local anti -fXa activity 
level… high andexanet dosing regimen” in the Synopsis, Section 3.1, Section 
3.3, Section 4.1, Table 4.  
• Clarified in Synopsis  that an interim analysis will be done when 450 patients 
complete their treatment period, and DSMB is to recommend early stopping process with relevant criteria.  
• Removed stratification factor of intended -usual -care-agent from analyses from 
the Synopsis, Section 10.5.4.4, and Section 10.6.3.  
• Clarified that local laboratory assays should be performed at specific timepoints as per Schedule of Activities. However, the requirements to perform complete assay panels described in Section 9.2.2. is only if available as per study site 
standard of care.  
• Updated that All ITT patients will be included in the primary analysis.  Patients with non -evaluable hemostatic efficacy due to clinical reasons will be treated as 
treatment failures in Section 10.5.3.1.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 15 Protocol Version and 
Date  Substantial Changes  
• Updated text for primary efficacy endpoint analysis to include “excellent or 
good as adjudicated by the blinded EAC”, “difference in proportions, and the 
proportions from the two groups”, and “analysis, OR p<” in Section 10.5.4.2.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 16 PROTOCOL S YNO PSIS 
Title A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in 
Patients Receiving an Oral Factor Xa Inhibitor  
Study Numb er 18-513 
Study Phase 4 
Total Number 
of Centers  Approximately 250 sites in North America, Europe, and Asia  
Objectives In oral  Factor Xa (FXa) inhibitor- treated patients with acute intracerebral bleeding, the 
objectives of this study are as follows:  
Primary Efficacy Objective:  
• To evaluate the effect of andexanet alfa (andexanet) versus usual care on the rate of 
effective hemostasis.  
Secondary Efficacy Objective:  
• To evaluate the effect of andexanet versus usual care on anti- fXa activity.  
Additional Efficacy Objectives:  
• To evaluate the effect of andexanet versus usual care on thrombin generation.  
• To evaluate the effect of andexanet versus usual care on neurologic function.  
• To assess the relationship between anti -fXa activity and the achievement of hemostatic 
efficacy.  
• To evaluate the effect of andexanet versus usual care on health -related quality of life.  
Safety Ob jectives:  
• To evaluate the occurrence of thrombotic events (TEs) at 30 days after randomization.  
• To evaluate in -hospital and 30 -day mortality (all -cause, cardiovascular [CV], and 
bleeding). 
• To evaluate the occurrence of invasive intracranial procedures post -randomization.  
• To evaluate the length of initial hospitalization for primary bleeding event.  
• To evaluate the rate of re- hospitalization at 30 days after randomization.  
• To evaluate adverse events (AEs) and vital signs.  
• To evaluate the immuno genicity of andexanet.  
Study Design 
 This is a randomized, multicenter clinical trial designed to determine the efficacy and safety of andexanet compared to usual care in patients presenting with acute intracerebral hemorrhage within 6 hours of symptom onset (from the baseline scan) and within 15 hours of taking an oral FXa inhibitor (from randomization).  The study will use a prospective, 
randomized, open- label design, as it is unfeasible to blind the Investigator to the treatment 
assignment given the many potential therapeutic options available under usual care treatment.  
The primary efficacy outcome will be adjudicated by a blinded Endpoint Adjudication 
Committee (EAC).  To support the adjudication of hemostatic efficacy, a blinded Imaging 
Core Laborato ry will review all available scans.  Approximately 900 patients are planned to 
be enrolled in the study.  
Once the Informed Consent Form (ICF) is signed, eligibility criteria are confirmed, and 
baseline assessments are performed, patients will be randomized  1:1 to receive either 
andexanet or usual care stratified by the site’s intended -usual -care- agent response and also 
the time from symptom onset to baseline scan.  Randomization must occur within 15  hours 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 17 following the last dose of the FXa inhibitor.  If a standard  of care local anti -fXa activity level 
obtained within 2 hours prior to consent is >  100 ng/mL for direct FXa inhibitors (apixaban, 
rivaroxaban or edoxaban), the patient may be enrolled, irrespective of the time of the last 
dose, and the patient should receive the high andexanet dosing regimen.  These measures are 
designed to ensure patients have sufficiently high anti -fXa activity.   
Usual care will consist of any treatment(s) (including no treatment) other than andexanet 
administered within 3 hours post- randomizat ion that the Investigator and/or other treating 
physicians consider to be appropriate.  For andexanet treatment, patients will receive one of 
two dosing regimens of andexanet based on which FXa inhibitor they received and the 
amount and timing of the most recent dose.  Andexanet will be given via an intravenous (IV) 
bolus administered over ~15 minutes (low dose) to 30  minutes  (high dose) followed 
immediately by a continuous infusion administered over ~120 minutes.  There will be no 
cross -over between treatm ent groups.  
It is intended that all patients initiate treatment as soon as possible after the treatment allocation is known.  For:  1) anti -fXa activity; and 2) diagnostic evaluations to support 
hemostatic efficacy (i.e., imaging tests, National Institutes  of Health Stroke Scale [NIHSS]), 
baseline is defined as the most recent assessment within 15 minutes and 120 minutes prior to randomization, respectively.  For post- baseline efficacy assessments, time 0 is defined 
as randomization.  
AEs including serious AEs (SAEs) and TEs, and survival will be followed through the 
Day 30 post- treatment visit for all patients (or to day 120 if applicable).  The study Schedule 
of Activities can be found in  Appendix A . 
The primary efficacy endpoint will be adjudicated based on data collected through 12 hours 
post-randomization.  The following data are planned to be captured:  imaging and clinical 
elements (brain Magneti c Resonance Imaging [MRI] or Computed Tomography [CT]), 
assessment using the National Institutes of Health Stroke Scale (NIHSS) performed by a person blinded to treatment allocation (Appendix E ), and concomitant medication entry and 
hospital records for rescue therapy.  
The blinded, independent EAC will oversee the adjudication of hemostatic efficacy, as well 
as all deaths and potential TEs.  All source  documents will be redacted to maintain the 
blinding of the EAC.  The independent EAC will be blinded to all anti -fXa activities and 
treatment assignments.  An independent Data Safety Monitoring Board (DSMB) will 
periodically review all safety data in aggr egate, and also conduct one formal  interim analysis 
on the primary efficacy endpoint after approximately 50% (450 patients) of the anticipated 
sample size has been adjudicated.  The DSMB will be empowered to make recommendations 
regarding study modificatio n or to suggest stopping the study early for reasons related to 
balance of risk and benefit.  The DSMB Charter outlines all activities of this Committee.  
If the decision is not to stop, a pre-planned sample size re- estimation (SSR) will be 
performed by the blinded DSMB statistician to reassess the required size of the study population based on estimation of the primary endpoint at the interim analysis. The 
maximum total number of patients enrolled may be increased to 1200 patients (with the maximal 300 additional patients). The SSR will be based on a conditional power (CP) using a promising zone with the boundary of 30% to 90%.  
Study Periods The study duration for most patients will be up to 37 days.  The study duration includes 
3 study periods as  follows:  
• Screening and Baseline Period:  < 1 day (Day 1)  
• Treatment Period:  < 1 day (Day 1)  
• Follow -up Period (all AEs, survival, antibodies):  ~30 days (Day 1 to the Day  30 study 
visit)  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 18 Patien ts with a positive anti -andexanet antibody response at the Day 30 visit should have 
additional follow up to approximately 120 days post -randomization.  
Inclusion 
Criteria All of the following criteria must be met for the patient to be eligible: 
1. Written inf ormed consent.  Either the patient or his or her legally authorized 
representative (LAR) if permissible by local or regional laws and regulations has been 
adequately informed of the nature and risks of the study and has given written informed consent prior  to Screening.  
o Deferred consent procedure is allowed where approved by local ethics committees.  In cases of deferred consent, the time of the study physician’s documented decision to include the patient into the study will serve as “time of consent” with respect to protocol -specific procedures.   
o In all cases where the patient does not sign informed consent prior to study entry, informed consent from the patient (or LAR) will be obtained as soon as 
realistically possible after inclusion in Study 18-513 and in accordance with the 
Declaration of Helsinki, International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice 
(GCP), the EU General Data Protection Regulation (GDPR), and national and 
local regulations.  
2. Age ≥  18 years old at the time of consent.  
3. An acute intracerebral bleeding episode, defined as an estimated blood volume of ≥ 0.5 mL to ≤  60 mL acutely observed radiographically within the cerebrum.  Patients 
may have extracerebral (e.g., subdural, subarachnoid, epidural) or extracranial (e.g., gastrointestinal, intraspinal) bleeding additionally, but the intracerebral hemorrhage 
must be considered the most clinically significant bleed at the time of enrollment.  
4. Performance of a head CT or MRI scan demonstrating the intracerebral bleeding within 
2 hours prior to randomization (the baseline scan may be repeated only once to meet 
this criterion).  
5. Treatment with an oral FXa inhibitor (apixaban [last dose 2.5 mg or greater], 
rivaroxaban [last dose 10 mg or greater], or edoxaban [last dose 30  mg or great er]: 
o ≤ 15 hours prior to randomization.  
o > 15 hours prior to randomization or unknown time of last dose, only if 1) the 
local anti- fXa activity >  100 ng/mL for direct fXa inhibitors (apixaban, 
rivaroxaban or edoxaban), and 2) the local anti -fXa activity lev el is obtained 
within 2 hours prior to consent, performed as per standard of care.  Note:  Patients 
enrolled in this manner should receive a high andexanet dosing regimen.  
6. Time from bleeding symptom onset < 6 hours prior to the baseline imaging scan.  Time  
of trauma (if applicable) or time last seen normal may be used as surrogates for time 
of symptom onset.  (If the baseline scan is repeated to meet Inclusion Criterion #4, the 
time from bleeding symptom onset must be < 6 hours prior to the repeat baseline 
imaging scan.)  
7. Female patients of childbearing potential and male patients with female partners of childbearing potential must follow protocol -specified guidance for avoiding pregnancy 
for 30  days after the last dose of study drug.  
8. Have a negative pregnancy test documented prior to enrollment (for females of 
childbearing potential).  
9. NIHSS score ≤  35 at the time of consent.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 19 Exclusion  
Criteria 
 If a patient meets any of the following criteria, he/she is not eligible to participate in this trial.  
1. Planned surgery, including Burr holes for hematoma drainage, within 12 hours after 
randomization.  Minimally invasive surgery/procedures not directly related to the treatment of intracranial bleeding and that are not expected to significantly affect 
hemato ma volume are allowed (e.g., Burr holes for intracranial pressure monitoring, 
endoscopy, bronchoscopy, central lines —Section  7.2, Section  7.3 and Appendix G ). 
2. Glasgow Coma Scale (GC S) score < 7 at the time of consent.  If a patient is intubated 
and/or sedated at the time of consent, they may be enrolled if it can be documented that 
they were intubated/sedated for non- neurologic reasons within 2 hours prior to consent.  
3. Purposefully left blank
 to align with the programmed database.   
4. Anticipation that the baseline and follow up brain scans will not be able to use the same imaging modalities (i.e., patients with a baseline CT scan should have a CT scan in follow up; similarly, for MRI).  
5. Expected survival of less than 1 month (not related to the intracranial bleed).  
6. Recent history (within 2 weeks) of a diagnosed TE or clinically relevant symptoms of the following: 
o Venous Thromboembolism (VTE:  e.g.,  deep venous thrombosis, pulmonary 
embolism [PE], cerebral venous thrombosis), myocardial infarction (MI), 
Disseminated Intravascular Coagulation (DIC), cerebral vascular accident, 
transient ischemic attack (TIA), acute coronary syndrome, or arterial systemic embolism (see Appendix H  for DIC scoring algorithm).  
7. Acute decompensated heart failure or cardiogenic shock at the time of randomization (see Appendix I  for cardiogenic shock definition).  
8. Severe sepsis or septic shock at the time of randomization (see Appendix I  for sepsis 
definition).  
9. The patient is a pregnant or lactating female.  
10. Receipt of any of the following drugs or blood products within 7 days prior to consent:  
a. Vitamin K Antagonist (VKA) (e.g., warfarin).  
b. Dabigatran.  
c. Prothrombin Complex Concentrate products (PCC, e.g., KCentra
®) or 
recombinant factor VIIa (rfVIIa) (e.g., NovoSeven®), or anti -inhibitor coagulant 
complex (e.g.,  FEIBA®), FFP, and whole blood.  
11. Past use of andexanet (or planned use of commercial andexanet).  
12. Treatment with an investigational drug <  30 days prior to consent.  
13. Any tumor -related bleeding.  
14. Known hypersensitivity to any component of andexanet.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 20 Test Product, 
Dose, and Mode  of 
Administration  Andexanet will be administered as an IV bolus, immediately followed by a continuous 
infusion.  There are two possible dosing regimens:  
Dose  Initial IV Bolus  Follow -on IV Infusion  
Low 400 mg at a target rate of 30 mg/min 
for ~15 minutes  480 mg at a target rate of 4 mg/min for 
120 minutes  
High 800 mg at a target rate of 30 mg/min 
for up to ~30 minutes  960 mg at a target rate of 8 mg/min for 
120 minutes  
Patients will receive a low or high dose according to the following table:  
FXa 
Inhibitor  FXa 
Inhibitor 
Last Dose  Timing of FXa Inhibitor Last Dose before 
Andexanet Initiation  
< 8 Hours  ≥ 8 Hours  > 15 Hours or 
Unknowna 
Rivaroxaban  10 mg  Low Dose  Low Dose  High Dose  
> 10 mg  High Dose  
Apixaban  ≤ 5 mg  Low Dose  
> 5 mg  High Dose 
Edoxaban  30 mg  Low Dose  
> 30 mg  High Dose  
a ONLY if 1) the local anti- fXa activity > 100 ng/mL for direct  fXa inhibitors (apixaban, 
rivaroxaban or  edoxaban), and 2) the standard  of care local anti -fXa activity 
level  is obtained  within 2  hours prior to consent.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 21    
Endpoints  Primary Efficacy Endpoin t 
Effective hemostasis 12  hours post -randomization as determined by the blinded EAC.  
Secondary Efficacy Endpoint  
• Percent change from baseline to nadir in anti -fXa activity during the first 2  hours 
post-randomization.  
Additional Efficacy Endpoints  
• Change from baseline in thrombin generation parameters (with Endogenous Thrombin 
Potential [ETP] as the primary measure) obtained at 1 and 12  hours post- randomization.  
• Proportion of neurologic deterioration, as defined by an NIHSS score increase ≥  4 or a 
GCS score decrease ≥  2 at 24 hours post -randomization versus baseline.  
• Change from baseline in Modified Rankin Scale (mRS) score at 30 days post -
randomization. 
• Change from baseline in NIHSS score obtained at 2, 3, 6, 12, 24, and 72 hours 
post-randomization  
• Change from baseline GCS score obtained at 2, 3, 6, 12, 24, and 72  hours 
post-randomization.  
• Proportion of patients with a ≥  7-point increase from baseline in NIHSS score at 
12 hours post- randomization.  
• Hemostatic efficacy evaluated using only imaging par ameters.  
• Proportion of patients receiving rescue therapy between 3 and 12 hours post-randomization.  
• Correlation analysis between anti -fXa activity and the achievement of hemostatic 
efficacy.  
• Health -related quality of life as assessed by the EuroQol -5 Dimension (EQ -5D) 
questionnaire at 30 days post -randomization. 
• Utility -weighted Modified Rankin Scale (uw -mRS) score at 30  days 
post-randomization.  
Safety Endpoints  
• Occurrence of TEs, confirmed by adjudication, through 30 days post -randomization.  
• In-hospital mortality (during index hospitalization; all- cause, CV, and  bleeding).  
• 30-day all -cause, CV, and bleeding related mortality (defined as any death within 72 
hours from randomization and not associated to the occurrent of an identified TE event).  
• Proportion of  patients with invasive intracranial procedures performed 
post-randomization to manage the intracranial hematoma and/or its complications.  
• Length of initial hospitalization for primary bleeding event.  
• Total time admitted to the intensive care unit during the initial hospitalization.  
• Proportion  of re -hospitalizations, including total number of re -hospitalizations and total 
days re -hospitalized, at 30 days
 post- randomization.  
• AEs and vital signs . 
• Antibodies to Factor X (FX), FXa, and andexanet.  
• Neutralizing antibodies to FX, FXa, and andexanet.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 22 Sample Size and 
Statistical Power  Approximately 900 patients (i.e., 450 patients per group) will be randomized 1:1 to receive either andexanet or usual care.  After accounting for early discontinuation rate and the type I 
error associated with the interim analysis, this sample size should have approximately 90% power to detect a 10% absolute difference between andexanet and usual care in the rate of 
effective hemostasis at an overall 0.05 two -sided overall significan ce level.  The rate of 
effective hemostasis is estimated to be approximately 70% and 80% for usual care and andexanet, respectively.  The expected rate of effective hemostasis in the andexanet 
population is based on efficacy results from ANNEXA -4.  A 10% higher rate of effective 
hemostasis represents a 33% risk reduction of not achieving it from the usual care, which is 
considered clinically meaningful.  
Statistical  
Analysis  The primary objective of the study is to compare the proportion of patients with effective hemostasis (excellent or good as adjudicated by the blinded EAC) between andexanet and usual care).   
For a patient to have excellent or good hemostatic efficacy, he or she must meet all of the 
following criteria: 
• NIHSS score of less than +7 point change from the baseline score at 12  hours 
post-randomization  
• No greater than 35% increase from baseline in hematoma volume at 12  hours 
post-randomization  
• Have not received rescue therapy (as defined in Section  7.4) between 3 and 12  hours 
post-randomization  
The following hypothesis will be evaluated:  
H
0:  π  UC – π  andexanet  = 0 
HA:  π  UC – π  andexanet  ≠ 0 
Analysis will be performed using a Cochran -Mantel Haenszel (CMH) test stratified by time 
from symptom onset to baseline imaging scan (<  180 minutes vs ≥  180 minutes).  The 
corresponding 95% confidence intervals for the difference in the proportion of participants with effective hemostasis between andexanet and usual care, and for the proportions will be 
provided. Missing values and/or non- evaluable hemostatic efficacy will be imputed.  
The study will be considered t o have met its primary efficacy objective if (1) the proportion 
of andexanet -treated patients with effective hemostasis is significantly higher than that in 
patients randomized to usual care with p  < 0.0310 at interim analysis when  approximately 
50% (450 p atients) of the anticipated sample size has been adjudicated  for their hemostatic 
data; or (2) p < 0.0277 at the end of the study.   
If the primary endpoint is statistically significant, the secondary endpoint will be tested at the same alpha level .  
The secondary endpoint is the percent change in anti -fXa activity from baseline to nadir 
during the first 2 hours post -randomization. The analysis of this endpoint will be  an Analysis 
of Covariance (ANCOVA) on the ranked data, including time from symptom o nset to 
baseline imaging scan (<  180 minutes vs. ≥  180 minutes), and baseline anti- fXa activity as 
covariates.  
The final analysis is controlled in a similar fashion using an alpha level of 0.0277.  
The overall family -wise error rate is controlled at alpha l evel of 0.05 and accounts for the 
interim and final analyses for the primary and secondary endpoints.  
Neurological status at 24 hours compared with baseline according to scoring on the NIHSS 
and GCS is included among the additional efficacy endpoints.  The  change from baseline to 
hour 24 for each scale will be analyzed using a linear mixed effects model while the binary 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 23 variable (proportion of neurological deterioration at 24 hours) will be analyzed using a 
stratified CMH test.  
The individual thrombin gener ation and mRS score (ordinal, dichotomous, and 
utility -weighted analyses) will be analyzed as well.  
For additional efficacy analysis refer to the Statistical Analysis Plan.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 24 LIST OF A BBRE VIATIONS AND TERMS 
Abbreviation  Definition  
AE Adverse Event  
AESI  AEs of Special Interest  
ANCOVA  Analysis of Covariance  
Andexanet  Andexanet Alfa  
CFR Code of Federal Regulations  
CI Confidence Interval  
CIOMS  Council for International Organizations of Medical 
Sciences  
CMH  Cochran -Mantel Haenszel 
COVID  Coronavirus Disease 2019  
CP Conditional Power  
CRF  Case Report Form  
CT Computed Tomography  
cTn cardiac Troponin  
CV Cardiovascular  
DBP  Diastolic Blood Pressure  
DIC Disseminated Intravascular Coagulation  
DSMB  Data Safety Monitoring Board  
DVT  Deep Vein Thrombosis  
EAC Endpoint Adjudication Committee  
eCRF  Electronic Case Report Form  
ECG  Electrocardiogram  
ED Emergency Department  
EDC Electronic Data Capture  
EQ-5D EuroQol -5 Dimension  
ETP Endogenous Thrombin Potential  
FDA (US) Food and Drug Administration  
FFP Fresh Frozen Plasma 
FX Factor X  
FXa Factor Xa  
GCP  Good Clinical Practice  
GCS  Glasgow Coma Scale 
GDPR  General Data Protection Regulation  
HIPAA  Health Insurance Portability and Accountability Act  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 25 Abbreviation  Definition  
ICrH  Intracranial Hemorrhage  
IEC Independent Ethics Committee  
INR International Normalized Ratio  
IRB Institutional Review Board  
ITT Intent -to-Treat  
IV Intravenous  
LAR Legally Authorized Representative  
LBBB left bundle branch block  
MedDRA  Medical Dictionary for Regulatory Activities  
MI Myocardial Infarction  
MRI  Magnetic Resonance Imaging  
mRS  Modified Rankin Scale  
NIHSS  National Institutes of Health Stroke Scale  
NSAID  Non-Steroidal Anti -Inflammatory Drug 
PaO 2/FIO 2  Arterial oxygen partial pressure/fractional inspired 
oxygen 
PCC Prothrombin Complex Concentrate  
PD Pharmacodynamic  
PE Pulmonary Embolism  
PK Pharmacokinetic  
PP Per Protocol  
PRBC  Packed Red Blood Cell  
rfVIIa  Recombinant factor VIIa  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SBP Systolic Blood Pressure  
SSR Sample Size Re- estimation  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
TE Thrombotic Event  
TEAE Treatment -Emergent Adverse Event  
TFPI  Tissue Factor Pathway Inhibitor  
TIA Transient Ischemic Attack  
ULN Upper Limit of Normal  
US United States  
uw-mRS  Utility -weighted modified Rankin Scale  
VKA  Vitamin K Antagonist  
VTE Venous Thromboembolism  
WBC White blood cells  
WHO -DD World Health Organization Drug Dictionary 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 26 1.0 INTRODUCTION  
The class of Nove l Oral Anticoagulants known a s direct Factor Xa (F Xa) inhib itors has 
consistently demonstrated comparable or super ior efficacy a nd/or safety relative  to its 
predecessors, Vitamin K Antagonists ( VKAs)  and Low Mol ecular Weight Hepar ins.  These 
agents (apixaban [Eliquis®], betrixaban [BevyxXa®], edoxaban [Savaysa®], rivaroxaban 
[Xarelto®]) are approved for the prevention of serious thromboembolic outcomes (e.g., stroke, 
deep vein thrombosis [DVT], pulmonary embolism  [PE]) and have become widely used in the 
United States (US) and worldwide.  One limitation to the use of FXa inhibitors has been the lack 
of an antidote to be used in cases of severe and/or life-threatening bleeding events.  Acute major 
bleeding occurs at observed rates of 2 -4% in pivotal stroke prevention trials in patients with 
nonvalvular atrial fibrillation  [1-3], and such events are often catastrophic.  Given the wide 
adoption and increasing use of FXa inhibitors, the prospect of major bleeding, especially in 
Intracranial Hemorrhage (ICrH) patients, has become a significant unme t medi cal need. 
Among the various types of bleeding, the most serious and consequential is ICrH, including intracerebral/intraventricular, subdural, subarachnoid, and epidural bleeding.  Patients with ICrH 
have particularly dismal outcomes, with 30- day mortality rates in excess of 30 -40%  [1-3] and a 
75% 1- year incidence of severe disability or death [4].  In the management of patients with ICrH, 
a primary therapeutic goal is the prevention of hematoma  expansion, which has been strongly 
associated with morbidity and mortality [5].  While investigation of the impact of hematoma 
expansion is limited by a lack of a unifying definition [6], a general consensus has arisen in 
recent years that a relative volume increase of 30 -35% or less compared to baseline is indicative 
of a lack of expansion [ 7-9]. 
For anticoagulated patients presenting with major bleeding, one key treatment objective is to 
rapidly reverse the effects of anticoagulat ion.  It is known from experience with VKA- related 
bleeding that reversal of anticoagulation is associated with improved hemostatic efficacy [ 7] and 
reduced mortality [ 10].  In bleeding patients anticoagulated with the direct thrombin inhibitor 
dabigatran, treatment with idarucizumab, a monoclonal antibody against dabigatran, results in a rapid and durable reversal of dilute thrombin time and ecarin clotting time [11].  However, until 
recently no agents had been approved for reversing the anticoagulation related to oral FXa inhibitors.  In addition, it is not known if reversal of anticoagulation is beneficial specifically to 
patients with ICrH.  
Andexanet alfa (andexanet ), a rationally designed, recombinant analog of endogenous human 
FXa, has been developed to rapidly and potently reverse FXa inhibition and restore physiologic 
coagulation.  It was granted accelerated approval by the US Food and Drug Administration 
(FDA) i n 2018 and initial conditional marketing authorization by the European Commission in 
2019.  Clinical studies to date have shown that andexanet rapidly reverses FXa inhibition in healthy volunteers and in bleeding patients, including those with ICrH.  Andexanet is also 
associated with a high rate of clinical hemostasis in patients with ICrH and in patients with other 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 27 types of major bleeding.  Details of the nonclinical and clinical experience with andexanet, 
including guidance for the Investigator, can be found in the Investigator’s Brochure (IB).  
Andexanet has not been compared to usual care in a randomized trial.  The present randomized trial will be performed to demonstrate improved hemostatic efficacy with andexanet compared to 
usual care in patients with  acute intracerebral hemorrhage while taking an oral FXa inhibitor.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 28 2.0 STUDY OBJECTIVES  
Table  1 summarizes the objectives and endpoints of this study in or al FXa inhibitor -treated 
patients with acute intracerebral hemorrhage.  
Table  1: Study 18 -513: Objectives and Endpoints  
Objectives  Endpoints  
PRIMARY EFFICACY   
● Evaluate the effect of andexanet versus usual 
care on the rate of effective hemostasis.  ● Effective hemostasis 12  hours post -randomization 
as determined by the blinded EAC.  
SECONDARY EFFICACY   
● Evaluate the effect of andexanet versus usual care on anti -fXa activity.  ● Percent change from baseline to nadir in anti -fXa 
activity during the first 2  hours 
post-randomization.  
ADDITIONAL EFFICACY   
● Evaluate the effect of andexanet versus usual care on thrombin generation.  ● Change from baseline in thrombin generation 
parameters (with ETP as the primary measure), 
obtained at 1 and 12 hours post- randomization.  
● Evaluate the effect of andexanet versus usual 
care on neurologic function.  ● Proportion of neurologic deterioration, as defined 
by an NIHSS score increase ≥  4 or a GCS score 
decrease ≥  2 at 24  hours post -randomization 
versus baseline.  
● Change from baseline in mRS score at 30 days 
post-randomization.  
● Change from baseline in NIHSS score obtained at 2, 3, 6, 12, 24, and 72  hours post- randomization.  
● Change from baseline GCS score obtained at 2, 3, 
6, 12, 24, and 72  hours post- randomization.  
● Proportion of patients with a ≥  7-point increase 
from baseline in NIHSS score at 12 hours 
post-randomization.  
● Hemostatic efficacy evaluated using only imaging 
parameters.  
● Proportion of patients using rescue therapy between 3 and 12  hours post- randomization.  
● Assess the relationship between anti -fXa activity 
and the achievement of hemostatic efficacy.  ● Correlation analysis between anti-fXa activity and 
the achievement of hemostatic efficacy.  
● Evaluate the effect of andexanet versus usual care on health -related quality of life.  ● Health -related quality of life as assessed by the 
EQ-5D questionnaire at 30 days 
post-randomization.  
● UW-mRS score at 30  days post- randomization.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 29 Table  1: Study 18 -513: Objectives and Endpoints  
Objectives  Endpoints  
SAFETY   
● Evaluate the occurrence of TEs at 30  days after 
randomization. ● Occurrence of TEs, confirmed by adjudication, 
through 30  days post- randomization.  
● Evaluate in-hospital and 30- day mortality 
(all-cause, CV, and bleeding).  ● In-hospital mortality (during index hospitalization; 
all-cause, CV, and bleeding).  
● 30-day all -cause, CV, and bleeding related 
mortality (defined as any death within 72  hours 
from randomization and not associated to the occurrence of an identified TE event).  
● Evaluate the occurrence of invasive intracranial procedures post -randomization. ● Proportion of patients with invasive intracranial procedures performed post -randomization to 
manage the intracranial hematoma and/or its complications.  
● Evaluate the length of initial hospitalization for primary bleeding event.  ● Length of initial hospitalization for primary bleeding event.  
● Total time admitted to the intensive care unit 
during the initial hospitalization.  
● Evaluate the rate of re -hospitalization at 30 days 
after randomization.  ● Proportion of re -hospitalizations, including total 
number of re -hospitalizations and total days 
re-hospitalized, at 30 days post- randomization.  
● Evaluate AEs and vital signs.  ● AEs and vital signs.  
● Evaluate the immunogenicity of andexanet.  ● Antibodies to FX, FXa, and andexanet.  
● Neutralizing antibodies to FX, FXa, and andexanet.  
AE = adverse event; CV  = cardiovascular; EQ- 5D = EuroQol- 5 Dimension; ETP = endogenous thrombin 
potential; FX  = Factor X; FXa  = Factor Xa; GCS  = Glasgow Coma Scale; mRS  = modified Rankin Scale; 
NIHSS  = National Institutes of Health Stroke Scale; TE = thrombotic event; uw -mRS  = utility -weighted 
modified Rankin Scale.  
  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 30 3.0 INVESTIGATIONAL PLAN  
3.1. Overall Study De sign and Plan:   Description 
This is a randomized clinical trial to determine the efficacy and safety of andexanet compared to 
usual care in patients presenting with acute intracerebral hemorrhage within 6 hours of symptom 
onset (from the baseline scan) and within 15 hours of taking a n oral FXa inhibitor (from 
randomization).  The study will use a prospective, randomized, open- label design, as it is 
unfeasible to blind the Investigator to the treatment assignment given the many potential 
therapeutic options available under usual care t reatment.  The primary efficacy outcome will be 
adjudicated by a blinded Endpoint Adjudication Committee  (EAC).  
Patients will typically be enrolled in the Emergency Department (ED) upon presentation with an 
acute intracerebral bleeding episode.  However, patients who experience an acute intracerebral 
hemorrhage while hospitalized in other hospital departments may also be enrolled.  
Approximately 900 patients will be enrolled in the study at approximately 250 sites in North 
America, Europe, and Asia. 
Once th e Informed Consent Form (ICF) is signed, eligibility criteria are confirmed, baseline 
assessments are performed, and the site’s intended -usual- care- agent answer (see Section  3.2.1) is 
documented, patients will be randomized 1:1 to receive either andexanet or usual care, stratified 
by the site’s intended-usual- care- agent response and also the time from symptom onset to 
baseline scan.  Randomization must occur within 15 hours following the last dose of FXa inhibitor.  If a local anti-fXa activity obtained within 2 hours prior to consent is > 100 ng/mL for 
direct FXa inhibitors (apixaban, rivaroxaban or edoxaban), and performed as per standard of care, the patient may be enrolled if the time of last FXa inhibitor dose is >15 hours or the time of 
the last dose is unknown, and the patient should receive the high andexanet dosing regimen.  These measures are designed to ensure patients have sufficiently high an ti-fXa activity.  Specific 
instructions related to anti- fXa activities obtained at a local laboratory are  contained i n the 
Laboratory Manual. 
Usual care will consist of any treatment(s) (including no treatment) other than andexanet 
initiated within 3 hours post -randomization that the Investigator and/or other treating physicians 
consider to be appropriate.  For andexanet treatment, patients will receive one of two dosing regimens of andexanet based on which FXa inhibitor they received (see Section 6.2 ) and the 
amount and timing of the most recent dose. 
Andexanet dosing should be initiated no later than 30 minutes after randomization and preferably 
within 2  hours of the baseline brain imaging scan ( Figure 1 ).  To accommodate dosing within 
2 hours of the baseline scan closest to randomization, reconst itution of andexanet prior to 
randomization will be allowed.  Andexanet will be given as an intravenous (IV) bolus 
administered over ~15 minutes (low dose) to 30 minutes (high dose), followed immediately by 
continuous infusion administered over ~120 minute s.  There will be no cross- over between 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 31 treatment groups.  Patients may be treated for bleeding with any unplanned rescue medications 
or intervention deemed to be clinically warranted, except andexanet in the usual care arm 
(see Section  7.2, Section  7.3, and Section  7.4 for specific guidance on use of rescue and 
concomitant medications). 
It is intended that all patients initiate treatment as soon as possible after randomization.  Patients 
allocated to andexanet arm should commence andexanet no later than 30 minutes post-
randomization and preferably within 2 hours of the baseline brain im aging scan. A schematic for 
events of a patient’s involvement in the study from baseline through approximately 12 hours after randomization can be found in Figure 1.  
Figure  1: Events Through the First 12 Hours After Enrollment  
s
 
 
1 Blinded evaluation at 12 hours and 24 hours post -randomization  
2 Reconstitution of andexanet prior to randomization will be allowed. Initiation of dosing should occur no 
later than 30  minutes after randomization and preferably within 2  hours of the baseline head scan.  
CT = computed tomography; FXa  = Activated Factor Xa; GCS  = Glasgow Coma Scale; h  = hour; 
labs = laboratories; min  = minutes, MRI = magnetic resonance imaging; mRS  = modified Rankin Scale; 
NIHSS  = National Institutes of Health Stroke Scale; TFPI=Tissue Factor Pathway Inhibitor; TG  = thrombin 
generation  
Note :  Dosing procedures begin after randomization.  Andexanet will be given as a bolus  over 15- 30 minutes 
followed by 120 -minute continuous infusion.  Treatment duration of usual care is dependent upon available therapy.  
A detailed listing of study procedures, including additional laboratory samples Day 1 through Day 30 is detailed in 
Appendix A . 

Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 32 Following baseline assessments, imaging evaluation will be performed at approximately 
12 hours following randomization.  All scans for individual patients should utilize a consistent 
imaging modality, scanner, and acquisition protocols/techniques whenever possible. Primary 
neurologic assessment will consist of evaluation of the National Institutes of Health Stroke Scale 
(NIHSS) at baseline and  at 12 hours.  The 12-hour and 24- hour assessments will be performed 
by study personnel who are blinded to the treatment allocation of the patient.  Additional NIHSS measurements performed at 2 hours, 3 hours, 6 hours, and 72 hours will be performed for sa fety 
monitoring purposes; these measurements may be blinded or unblinded.  Following the 12-hour assessment, patients will return for a follow -up visit at Day 30 (+7) and follow-up phone calls on 
Day 7 (+3) and Day 14 (+6).  s (a detailed Schedule of Activities is provided in Appendix A ).  
An additional visit is required for patients with a positive anti- andexanet antibody response at the 
Day 30 visit approximately 120 days post-randomization, or within 30 days of when the positive 
test is made known to the Investigator, whichever is later. 
The adjudication of hemostatic efficacy will be overseen by an independent EAC, using a rating 
system develo ped based on the study from Sarode, et al [ 7] (Appendix B ) and updated in recent 
International Society on Thrombosis and Haemostasis guidelines on hemostasis endpoints in clinical trials [9].  For this study, hemostatic efficacy will be based on assessment of neurologic 
status determined by NIHSS, and the use of rescue therapy, in addition to hematoma expansion.  Hematoma expansion between baseline and 12 hours will be assessed using serial brain imaging 
(computed tomography [CT] or magnetic resonance imaging [MRI]) read by a blinded core laboratory, and clinical assessment will be done by study personnel blinded to treatment 
allocation.  Effective hemostasis (i.e., a rating of “good” or “excellent”) will be defined as no 
greater than a 35% increase in hematoma volume AND no neurologic deterioration on the 
NIHSS of +7 or greater at 12 hours post-randomization, AND no adminis tration of rescue 
therapy between 3 hours and 12 hours post- randomization (defined in Section  7.4).  A patient 
that meets any of these 3  criteria will be considered to have “symptomatic hematoma 
expansion.” 
The EAC will also adjudicate all potential TEs (AEs of special interest [AESI]) and deaths.  The 
EAC will be blinded to all anti- fXa activity levels and treatment assignment.  Detailed practices 
and policies of the EAC will be delineated in a separate Adjudication Charter.  
The Imaging Core Laboratory readers will be blinded to treatment assignment, anti -fXa activity  
adjudicated outcomes, and clinical management for all patients, and, to the extent pos sible, will 
use the same standardized methodology to analyze all scans.  Parameters to be measured include, 
but are not limited to location of hematoma, hematoma volume and midline shift.  The policies 
and procedures of the Imaging Core Laboratory will be detailed in separate guidance documents, 
which include a Core Laboratory Charter and/or Standard Operating Procedures. 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 33 To provide oversight of safety monitoring and to review the interim efficacy and safety data 
while the study is ongoing, a Data Safety Monitoring Board (DSMB) will be convened (see 
Section  10.7 ).  The DSMB will meet periodically, approximately every 6 months to review 
efficacy and saf ety data.  A formal interim analysis of efficacy will be conducted after 
approximately 50% of the anticipated sample size has been adjudicated.  Safety outcomes to be 
evaluated include Serious Adverse Events (SAEs) and other AEs, with special attention to TEs 
(AESI).  The DSMB will determine whether the occurrence of TEs in aggregate (related or not) 
warrant changes to the study.  The DSMB may recommend termination of the study for efficacy 
results beyond reasonable doubt, or for any safety concern that is felt to outweigh potential 
benefits, wherein clear, consistent, and persistent evidence of net harm that overwhelms any 
benefit should be apparent.  The DSMB rules to modify the study design or stop the study for 
safety or efficacy will be detailed in the DSMB Charter.  
To minimize the effects of blood pressure on hematoma expansion, Investigators are reminded to have a goal of maintaining systolic blood pressure (SBP) at a target of 140 mm Hg as medically 
warranted in both treatment arms [12].  Use and timing of administration of Packed Red Blood 
Cell (PRBC) transfusion, transfusion of other blood products (e.g., whole blood, platelets, plasma), administration of coagulation factors and hemostatic agents, and diagnostic or 
therapeutic procedures for bleeding following randomization will be documented in the Case 
Report Forms (CRFs).  
3.2. Blinding and Randomization  
3.2.1. Randomization 
This study will be randomized 1:1 andexanet to usual care, stratified by: 
• Intended-usual- care-agent; and 
• Time from symptom onset to baseline imaging scan (<  180 minutes vs ≥ 180 
minutes).  
To account for potential differences in the demographics or baseline severity of patien ts who 
receive Prothrombin Complex Concentrate (PCC) products  (e.g., KCentra®) or recombinant 
factor VIIa (rfVIIa) (e.g., NovoSeven®), anti-inhibitor coagulant complex (e.g., FEIBA®), or 
other plasma- derived coagulation factor concentrates, or a regional difference in the use of these 
agents, randomization will be stratified by an intended-usual- care- agent (plasma-derived 
coagulation factor concentrates vs. other) determined on a patient-by-patient basis.  The intended-usual- care- agent is determin ed by the Investigator and is the Investigator’s best 
determination of what type of therapy will be used for the patient, in the event that the patient is randomized to the usual care arm.  In addition, to account for potential imbalances between 
treatment groups in baseline factors known to be predictive of hematoma expansion, 
randomization will also be stratified by the time from symptom onset to baseline imaging scan 
(< 180 minutes vs ≥ 180 minutes).  The randomization scheme will be generated by the Sponsor. 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 34 3.2.2. Blinding  
To avoid bias, the study treatment assignment and anti- fXa activity levels will be blinded to the 
independent EAC and the Imaging Core Laboratory.  However, because of the many therapeutic 
options available to Investigators to treat patients  randomized to usual care, it is considered 
unfeasible to blind all study personnel (especially those directly involved in the care of an enrolled patient) to treatment assignment.  Thus, the study treatment allocation of each patient 
will be unblinded to the local Investigator and most of the local site study team.  However, to 
perform neurologic assessments to support efficacy endpoints (particularly NIHSS and Glasgow 
Coma Scale [GCS]) at 12 - and 24-hours following randomization, individuals at each site who 
are tasked with these assessments at these time -points will be blinded.  Furthermore, the Sponsor 
will remain blinded to adjudication outcomes, post -randomization anti -fXa activities, and 
imaging results.  Blinding processes and procedures are outlined in a separate Blinding Plan.  
3.3. Duration of S tudy 
The study duration for most patients will be up to 37 days.  Data collection and follow up begins 
once informed consent is signed.  The study duration includes 3 study periods as follows: 
• Screening and Baseli ne Period:  < 1 day (Day 1) 
• Treatment Period:  < 1 day (Day 1)  
• Follow-Up Period (all AEs, survival, antibodies):  ~30 days (Day 1 to the Day 30 
study visit)  
Patients with a positive anti -andexanet antibody response at the Day 30 visit should have 
additional follow up to approximately 120 days post-randomization. 
3.3.1. Study Population  
The study will enroll patients who have recently taken an oral FXa inhibitor (i.e., within 15 hours 
prior to randomization) with an acute intracranial bleeding episode.  If a local anti-fXa activity 
obtained within 2 hours prior to consent is > 100 ng/mL for direct FXa inhibitors (apixaban, 
rivaroxaban or edoxaban), and performed as per standard of care , the patient may be enrolled if 
the time of last FXa inhibitor dose is >  15 hours or the time of the last dose is unknown, the 
patient should receive the high andexanet dosing regimen. 
Due to their anatomic location and spatial constraints, intracerebral bleeds have a markedly poor 
prognosis, even in relationship to other major bleeding events [1].  Within the intracerebral 
hemorrhage population, it is appropriate to identify those patients at greatest risk for hematoma expansion, as this event is associated with poor clinical outcomes [5].  To this end, it is well 
appreciated that a shorter time interval between the onset of symptoms and clinical presentation is associated with an increased risk of hematoma expansion, with the greatest risk within the first 
3 hours after symptom onset [ 13].  While the course of an intracerebral hemorrhage event in the 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 35 setting of therapeutic FXa inhibition is not fully known, a re cent study reported a 38% incidence 
of hematoma expansion at a median follow-up time of 21 hours after presentation [ 14], 
suggesting that bleeding continues to occur throughout the first 24 hours.  Thus, to ensure that 
enrolled patients are at risk for hematoma expansion, potential candidates will be excluded if the 
time from symptom onset to the baseline scan is greater than 6 hours.  
It is important to note that andexanet does not directly repair bleeding lesions – it restores normal coagulative mechanisms in patients with acquired coagulopathy due to their anticoagulated state.  
Therefore, it is possib le that certain defects, perhaps by virtue of their size, flow rate, or other 
coagulopathic mechanisms (e.g., platelet dysfunction), may not be amenable to anticoagulant reversal alone.  Because patients with such lesions are unlikely to benefit from andex anet, 
potential patients with a GCS score < 7, a NIHSS score > 35, or a hematoma volume ≤ 0.5 or ≥ 60 mL will be excluded from the study. 
Importantly, to ensure that enrolled patients are experiencing major bleeding associated with therapeutic anticoagulat ion with FXa inhibitors, it would be ideal to determine anti -fXa activity 
at baseline.  However, because:  1) local anti -fXa activity testing is not available at all hospitals; 
and 2) there is no standardized clinical assay for anti- fXa activity, it is not possible to use 
anti-fXa activity as a universal marker of anticoagulation for purposes of enrollment into the 
study.  Therefore, as a surrogate for elevated anti- fXa activity, the eligibility criteria restrict 
enrollment to patients who received their last dose of FXa inhibitor within 15  hours prior to 
randomization.  The 15-hour time-point was selected to enrich the study population with patients 
with anti- fXa activity levels within therapeutic ranges.  However, if local anti -fXa results are 
available, t hey may be used to qualify a patient where the last dose of anti- FXa inhibitor is 
> 15 hours or unknown only if 1) the local anti- fXa activity is >  100 ng/ mL for 
direct fXa  inhibitors (apixaban, rivaroxaban or edoxaban), and  2) the local anti- fXa activity level 
is obtained within 2 hours prior to consent, performed as part of standard  of care. The samples 
for anti- fXa activity (as well as for thrombin generation) collected at baseline and post -baseline 
for later analysis at a central laboratory, are the samples that will be used for analysis of secondary and additional efficacy outcome measures. 
3.3.2. Rationale for the Key Efficacy Endpoints  
The Phase 2 and Phase 3 trials of andexanet used reversal of anticoagulation endpoints as assessed by anti -fXa activity, anticoagulant free fraction, and thrombin generation.  In this study, 
hemostatic efficacy is being studied as the primary efficacy outcome, while the reversal of anticoagulation is being investigated as the secondary efficacy outcome.  The timing of all 
endpoints is anchored on randomization. 
3.3.2.1. Hemostatic Efficacy  
Because of the clinical importance of hematoma expansion, CT/MRI -based volumetric 
measurement is considered to be the most direct way to evaluate hemostatic efficacy and will 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 36 constitute the primary assessment of this endpoint.  That said, it is acknowledged that an 
evaluation of clinical status is potentially important to better ascertain the global benefit of an 
intervention.  In the acute phase, the best clinical measure of focal neurologic change is captured 
by the NIHSS ( Appendix E ).  Accordingly, for the purposes of evaluating the primary endpoint, 
the NIHSS will be measured by blinded personnel at 12 hours following randomization. 
In addition, another important clinical metric of efficacy is the durability of therapy.  Therefore, 
the use of pro-coagulant factor infusions (e.g., 3- or 4- factor PCC/activated PCC, rfVIIa, plasma, 
fresh frozen plasma [FFP] and anti -inhibitor coagulant complex [e.g., FEIBA®]), whole blood 
(see Table  5), hemostatic therapies, or an intervention/surgery intended to treat the hematoma at 
any time between 3 and 12 hours after randomization will result in the patient being considered having poor/none hemostatic efficacy in both treatment groups. 
Given the above considerations, the adjudication of hemostatic efficacy will be based on a 
combination of imaging and clinical findings (Appendix B ).  If a patient has an increase in 
hematoma volume > 35% from b aseline at any time between the end of initial randomized 
treatment and 12 hours post-randomization, they will be considered to have poor/none 
hemostatic efficacy.  Additionally, if a worsening from baseline in NIHSS score of +7 or more is 
observed at 12 hours, a patient will be considered to have poor/none hemostatic efficacy.  
Finally, if a patient receives rescue therapy (as delineated above), they will also be considered to 
have poor/none hemostatic efficacy.  Overall, if a patient should meet any one of the above 
criteria, they will be considered to have “symptomatic hematoma expansion” (see Section  7.4). 
3.3.2.2. Anti-fXa Activity  
Anti-fXa activity was chosen as the m ost re levant pharmacodynamic ( PD) marker to evaluate the 
biochemical rev ersal of an ticoagula tion based on several mechanistic and empiric observations: 
• In Phase 2 dose ranging trials with rivaroxaban and apixaban in patients who had 
undergone total knee replacement surgery or had symptomatic acute venous thrombosis, increasing the dose of the anticoagulant correlated with increased plasma drug concentration and increased frequency and severity of bleeding [15, 16]. 
• Plasma concentration of a FXa inhibitor correlates well with ex vivo  anti-fXa activity  
[17, 18] . 
• The unbound plasma concentration of apixaban but not t otal plasma concentration 
correlates with anti- fXa activity in patients treated with andexanet in Study  12-502. 
• Only the free, unbound plasma fraction of FXa inhibitor appears to account for the anticoagulant effects of the FXa inhibitors based on a critic al level below which anti -
fXa activity is lost [19-21]. 
• In animal models of blood loss, decrease in the plasma free fraction of FXa inhibitor and/or anti-fXa activity correlates with reduction in blood loss [15, 22] . 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 37 • In pati ents with intracerebral bleeding while anticoagulated with FXa inhibitors, there 
was a strong positive association between baseline anti -fXa activity and the later 
occurrence of hematoma expansion [8]. 
3.3.3. Rationale for the Dose Regimen of Andexanet 
Patients will receive one of two doses of andexanet based on the specific anticoagulant taken and 
timing of the last dose.  
The andexanet dosing regimens to be examined in this study are as follows: 
• Low dose:  400 mg IV bolus followed by a continuous infusion of 480 mg at 4 
mg/min.  
• High dose:  800 mg IV bolus followed by a continuous infusion of 960 mg at 8 mg/min.  
The continuous infusion will last approximately 120 minutes for all patients.  A dosing schema, 
categorized by FXa inhibitor and time from last dose, is provided in Table  4. 
The dose s in this study are w ithin the range of doses and inf usion dura tions s tudied pre viously in 
Study 12-502 and the Phase 3 studies (14-503 and 14-504).  Data from the Phase 3 studies with 
apixaban and rivaroxaban confirm the levels of FXa inhibition and recovery of thrombin generation observed in the Phase 2 study.  The se doses of a ndexane t correspond to decr eases in 
anti-fXa activi ty that corre late with no rmalization of hemosta sis as measured by a thrombin 
gene ration a ssay.  The change to the lower dose (400 mg) at 8 hours was based on the 
pharmacokinetic (PK) -PD model that predicted the time at which equivalent anti- fXa activity 
reversal and thrombin generation normalization would be achieved. 
In addition to the above, the doses for this study (18-513) were shown to substantially reduce 
anti-fXa activity and increase thrombin generation in a Phase 3b/4 study where andexanet was 
given to patients receiving a FXa inhibitor who had acute major bleeding (Study 14-505 [ANNEXA- 4]). 
3.4. Safety Plan and Monitoring 
The study will be conducted in patients who, by virtue of their condition, will typically be in acute care settings such as intensive care units and EDs.  It is anticipated that patients with acute 
intracranial bleeding will remain hospitalized for well over 12 hours, the timeframe for the 
primary efficacy evaluations.  During the first 24 hours after randomization (Study Day 1), AEs, 
vital signs, clinical neurologic testing, and brain imaging will be performed to monitor safety.  If 
a patient has a clinically significant, new or worsening, focal or global neurologic deficit relative 
to baseline (e.g., an increase from baseline in the NIHSS score of 5 or greater), that is not readily 
explainab le by an alternate etiology (e.g., sedatives, infection), Investigators will be requested to 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 38 pursue additional brain imaging.  Investigators will also be allowed to scan patients for any 
medically indicated reason at their discretion.  
After Study Day 1, all patients will be followed for AEs (including TEs) through the Day 30 visit.  Survival status will be documented through Day 30, and the cause and date/time of death 
will be recorded, if applicable.  Finally, patients will be assessed for antibodies to FX , FXa, and 
andexanet at the Day 30 visit. If a patient has a positive anti -andexanet antibody response at the 
Day 30 visit, they will return for a follow up anti- andexanet antibody test approximately 
120 days after randomization, or within 30 days of when the positive test is made known to the Investigator, whichever is later.  
Whether or not patients remain in the hospital, they w ill undergo the Study Day  2, Day 3, Day 7 
(phone call), Day 14 (phone call), and Day 30, and Day 120 (as applicable) Follow-up visits to 
assess outcomes.  
The independent EAC, in addition to adjudicating the primary efficacy endpoint, will also adjudicate all potential TEs using pre -defined criteria as described in the Adjudication Charter, 
as well as AESI and deaths.  In additi on, the independent DSMB will be empowered to 
recommend modifying or stopping the trial for safety reasons if warranted.  
3.5. Benef it and Risk Assessment 
FXa inhibitors are a significant therapeutic advance for several indications.  However, a significant risk of anticoagulation with FXa inhibitors is the prospect of uncontrolled major 
bleeding.  Patients enrolled in this study will have had an acute intracerebral bleeding episode in the setting of recent use of an FXa inhibitor.  These bleeding episodes may be life -threatening, 
result in severe organ compromise, and/or prove fatal without rapid control of bleeding and resuscitative measures.  Andexanet may be beneficial in reversing anticoagulation and, thus, removing anticoagulation as a contributor to the ongoing bleeding.  In addition to any personal 
benefit to individual patients, there is a potential benefit to all current and future patients treated 
with andexanet (and, more generally, all patients taking FXa inhibitors) from the insights gained 
through this clinical study.  The risks of study participation involve the risk of experiencing an 
AE related to andexanet or to the study procedures.  To date, no major safety issues directly 
attributable to andexanet have definitively emerged in clinical studies.  However, whenever 
chronic anticoagulation is reversed in patients with an indication to receive it, the risk of TEs is 
increased [23-25].  This risk must be balanced against the need to control the acute bleeding.  
The PD effect of andexanet is short.  Therefore, shortly after the infusion is discontinued and once bleeding is controlled, it will be possible to return the patient to a therapeutically 
anticoagulated state as needed.  It is recommended that the Investigator carefully weigh the risk 
of re-bleeding against the risk of thrombosis when considering whether to resume 
anticoagulation for the patient.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 39 Some patients enrolled in this study will receive current usual care therapies for their acute 
intracerebral bleeding.  While it could be reasonably argued that, in a critica lly ill bleeding 
patient, denial of use of an agent conditionally proven to rapidly reverse anti- fXa activity is 
unethical in a clinical setting where it is commercially available, it should be noted that, at 
present:  1) it is not definitively known if anti- fXa reversal is associated with clinical benefit; and 
2) the potential risks of rapid reversal, including the risks directly attributable to andexanet, are not well defined. 
Enrolled patients will have additional blood samples taken for assessment of various biomarkers 
of coagulation status, but the additional blood loss from phlebotomy will be minimal.  The 
results of several of these blood tests, as well as other assessments associated with the study 
(e.g., imaging, physical exams, and clinical status metrics) will provide data that may allow 
Investigators to positively influence management of enrolled patients.  Additionally, the results 
of the study will benefit patients with FXa inhibitor- induced acute intracerebral bleeding 
generally  by gaining detailed insights into the natural history of this condition. 
Based on the above conside rations, the pot ential risks to patients in this study are justifiable and 
balanced by the potential benefits. 
3.5.1. COVID-19 
3.5.1.1. Vaccination 
Following a review of the available coronavirus disease 2019 (COVID -19) vaccine data (e.g., 
Pfizer/BioNTech, Moderna, AstraZeneca, Johnson & Johnson), it is unlikely that the immune 
response to a COVID -19 vaccine (and therefore the efficacy of the vaccination) would be 
diminish ed with concomitant administration of andexanet, based on andexanet’s mechanism of 
action.  There is currently no available information evaluating the safety and efficacy of 
COVID- 19 vaccines in participants treated with andexanet.  
Local and national guidelines should be consulted for recommendations related to COVID-19 vaccination. 
3.5.1.2. Potential Risks and Mitigation Measures 
Acute intracerebral hemorrhage can cause irreversible morbidity and even mortality if untreated.  
As such, and because existing treatment  options may be less effective than andexanet, the benefit 
a participant may receive from joining this investigational study is potentially significant.  The potential risks identified and mitigation measures put in place in light of the COVID -19 
pandemic are provided in Appendix F .  The site Investigator will balance the risk/benefit 
considerations in the study participant taking these factors into account. 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 40 4.0 SELECTIO N OF STUDY PO PULATIO N AN D CRI TERIA FOR 
WITHDRAWAL  
4.1. Inclusion Criteria  
To be e ligible for study enrollm ent, potential study patients must sa tisfy all of the following 
inclusion cr iteria: 
1. Written informed consent.  Either the patient or his or her legally authorized 
representative (LAR) if permissible by local or regional laws and regulations  has been 
adequately informed of the nature and risks of the study and has given written informed consent prior to Screening. 
○ Deferred consent procedure is allowed where approved by local ethics committees.  In cases of deferred consent, the time of the study physician’s documented decision to include the patient into the study will serve as “time of consent” with respect to protocol- specific procedures.  
○ In all cases where the patient does not sign informed consent prior to study entry, informed consent from the patient (or LAR) will be obtained as soon as realistically possible after inclusion in the tri al and in accordance with the Declaration of Helsinki, 
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP), the EU General Data Protection Regulation (GDPR), and national an d local regulations.  
2. Age ≥ 18 years old at the time of consent. 
3. An acute intracerebral bleeding episode, defined as an estimated blood volume ≥ 0.5 to ≤ 60 mL acutely observed radiographically within the cerebrum.  Patients may have extracerebral (e.g., su bdural, subarachnoid, epidural) or extracranial (e.g., 
gastrointestinal, intraspinal) bleeding additionally, but the intracerebral hemorrhage must 
be considered the most clinically significant bleed at the time of enrollment.  
4. Performance of a head CT or MR I scan demonstrating the intracerebral bleeding within 
2 hours prior to randomization (the baseline scan may be repeated only once to meet this 
criterion).  
5. Treatment with an oral FXa inhibitor (apixaban [last dose 2.5 mg or greater], rivaroxaban [last dose  10 mg or greater], or edoxaban [last dose 30 mg or greater]: 
○ ≤ 15 hours prior to randomization.  
○ > 15 hours prior to randomization or unknown time of last dose, only if 1) the local anti-fXa activity >  100 n g/mL for direct fXa inhibitors (apixaban, rivaroxaban or 
edoxaban), as per standard of care, and 2) the local anti- fXa activity level is obtained 
within 2 hours prior to consent.  Note:  Patients enrolled in this manner should receive a high andexanet dosing regimen. 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 41 6. Time from bleeding symptom onset < 6 hours prior to the baseline imaging scan.  Time 
of trauma (if applicable) or time last seen normal may be used as surrogates for time of 
symptom onset.  (If the baseline scan is repeated to meet Inclusion Criterion #4, the time from bleeding symptom onset must be < 6 hours prior to the repeat baseline imaging 
scan.)  
7. Female patients of childbearing potential and male patients with female partners of childbearing potential must follow protocol-specified guidance for avoiding pregnancy for 30 days after the la st dose of study drug. 
8. Have a negative pregnancy test documented prior to enrollment (for females of childbearing potential). 
9. NIHSS score ≤ 35 at the time of consent. 
4.2. Exclusion Criteria  
If a patient meets any of the following criteria, he or she is not eligible to participate in this trial:  
1. Planned surgery, including Burr holes for hematoma drainage, within 12 hours after randomization.  Minimally invasive surgery/procedures not directly related to the 
treatment of intracranial bleeding and that are not expected to significantly affect hematoma volume are allowed (e.g., Burr holes for intracranial pressure monitoring, endoscopy, bronchoscopy, central lines—Section  7.2, Section  7.3 and Appendix G ). 
2. GCS score < 7 at the time of consent.  If a patient is intubated and/or sedated at the time of consent, they may be enrolled if it can be documented that they were intubated/sedated for non-neurologic reasons within 2 hours prior to consent. 
3. Purposefully left blank to align with the programmed database. 
4. Anticipation that the baseline and follow up brain scans will not be able to use the same imaging modalities (i.e., patients with a baseline CT scan should have a CT scan in follow up; similarly, for MRI).  
5. Expected survival of less than 1 month (not related to the intracrani al bleed).  
6. Recent history (within 2 weeks) of a diagnosed TE or clinically relevant symptoms of the following:  
○ Venous Thromboembolism (VTE:  e.g., deep venous thrombosis, PE, cerebral venous thrombosis), myocardial infarction (MI), Disseminated Intravascular Coagulation (DIC), cerebral vascular accident, transient ischemic attack (TIA), acute coronary syndrome, or arterial systemic embolism (see Appendix H  for DIC scoring 
algorithm).  
7. Acute decompensated heart failure or cardiogenic shock at the time of randomization (see Appendix I  for cardiogenic shock definition). 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 42 8. Severe sepsis or septic shock at the time of randomization (see Appendix I  for sepsis 
definition).  
9. The patient is a pregnant or lactating female.  
10. Receipt of any of the following drugs or blood products within 7 days prior to consent: 
a. VKA (e.g., warfarin). 
b. Dabigatran. 
c. PCC (e.g., KCentra®) or rfVIIa (e.g. , NovoSeven®), or anti-inhibitor coagulant 
complex (e.g., FEIBA®), FFP, and whole blood. 
11. Past use of andexanet (or planned use of commercial andexanet). 
12. Treatment with an investigational drug < 30 days prior to consent. 
13. Any tumor- related bleeding.  
14. Known hypersensitivity to any component of andexanet. 
4.3. Criteria for Discontinuation from the Study  
A patient m ay elect to discontinue participation in the  study a t any time.  However, all efforts 
must be made to follow patients for the full duration of the study and to encourage all patients to 
complete the Day 30, and Day 120 (as applicable) contact.  
If patients cannot or will not return for visits, the Investigator (or their designee) should attempt 
to contact them by telephone or other means; those who cannot be contacted should be 
considered lost to follow-up. 
Reasons for all study w ithdrawals w ill be recorded.  If a patient withdraws from the study, the 
patient may request destruction of any samples taken and not tested, and the Investigator must 
document this request in the site study records. 
Patients who discontinue study procedures for reasons other than withdrawal of consent can still 
have Day 30 mortality status collected. 
4.4. Criteria for Discontinuation of Andexanet  
Andexanet may be prematurely discontinued for a number of reasons, including:  
• Any intolerable AE that cannot be ameliorated by appropriate medical intervention or 
that in the opinion of the Medical Monitor or Investigator would lead to undue risk if the patient were to con tinue on treatment. 
Patients who discontinue study drug should still continue in the study.  Patients who discontinue 
the study after receiving any amount of andexanet should undergo all follow-up safety 
procedures. 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 43 Reasons for all discontinuations of andexanet will be recorded. 
4.5. Patient  Replacement 
Patients who are discontinued prematurely from the study will not be replaced.  The study will 
continue to enroll patients until approximately 900 patients have been randomized. 
4.6. Study Completion  
Study completion for each patient is defined a s completion of the Day 30 visit or, at a minimum, 
the time at which Day 30 mortality status is recorded. For patients with a positive anti ‑andexanet 
antibody response at the Day 30 visit, study completion is defined as completion of the follow ‑up 
visit approximately 120 days post ‑randomization, or within 30 days of when the positive test is 
made known to the Investigator, whichever is later. 
All events and analyses occurring by Day 30 will be described in a primary clinical study report. 
Additional events and analyses for the period between Day 30 and Day 120 (if applicable) will 
be described in a safety follow -up clinical study report. 
In some countries, “study completion” may also be considered the same as “end of trial.”  
4.7. End of the Trial  
The end of the trial is defined as the last visit of the last patient in the trial.  For patients who 
have a positive anti-andexanet antibody response at the Day 30 visit, the follow -up visit for an 
anti-andexanet antibody test approximately 120 days after randomization, or within 30  days of 
when the positive test is made known to the Investigator, whichever is later, will be considered 
their last study visit.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 44 5.0 ENRO LLMENT AND  STUDY P ROCEDURES 
A summary of the patient v isits and c linical evalua tions can be found in Appendix A .  Details on 
efficacy and safety assessments can be found in Section  9.0. 
5.1. Visit Proc edures (Days 1 to 30–37) 
5.1.1. Screening and Enrollment 
Patient s will be considere d to be in screening once the ICF has been signed.  Patients will be 
considered enrolled once they are randomized.  Patients for whom the ICF is signed, but are 
ultimately not rand omized, will be considered screen  failures.  
Laboratory assessments or procedures performed per standard of care at presentation of acute illness, but before signing of informed consent, may be used to assess eligibility. 
The visit procedures are described in the Schedule of Activities (Appendix A ). 
5.2. Unscheduled Visit 
Additiona l clinica l visits  may be scheduled a t the Inves tigators’ dis cretion in order to follow or 
evaluate AEs.  T he reason  for an unscheduled visi t will be recorded. 
The following must be p erformed a t an unsche duled vis it: 
• Record the reason for the unscheduled visit. 
• Record AEs since last study visit.  
• Record use of concomitant medication since last study visit.  
Additional procedures may be pe rformed at an unschedule d visi t as deemed nece ssary by the 
Inves tigator.  These may include any of the central or local laboratory testing done at scheduled 
visits, vital signs, additional evaluations for bleeding, or assessment of AEs. 
5.3. Early Termination V isit 
An Early Termination visit will be conducted if the patient withdraws consent from the study 
before the Day 30 Follow- Up visit.  Procedures at this visit will include the following: 
• Record the reason for early termination. 
• Record AEs since last study visit.  
• Record use of concomitant medication since last study visit. 
• Record dates of use of anticoagulant(s) on the anticoagulant CRF. 
• Perform a final assessment of bleeding (if p atient withdraws from the study prior to 
the 12- hour time -point).  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 45 • Modified Rankin Score /scale.  
• EQ-5D. 
• Survival status. 
• Collect central laboratory specimens for antibodies (anti- andexanet, anti -fX, anti- fXa, 
and neutralizing antibodies). 
Vital signs and lo cal laboratory assessments for complete blood count and chemistry should also 
be performed at Early Termination only if these assessments have not yet been performed at any 
point during treatment.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 46 6.0 DRUG SUPPLIES AND DOSING  
6.1. Formulation  
Andexanet is supplied i n single- use, type I gla ss vials and contains 200 mg/vial as a lyophiliz ed 
produc t for reconstitution for IV in jection (at 10 m g/mL after recons titution).  The compos ition 
is listed in Table  2.  The  lyoph ilized produc t must be recons tituted using Sterile Water for 
Injection bef ore use.  For deta ils on reconstituti ng/ preparing andexanet, pl ease re fer to the 
Pharmacy Manual. 
Table  2: Reconstitution Volumes and Composition for Andexanet  
Vial Contents  200 mg Vial  
Reconstitution Volume  20.0 mL WFI  
WFI = Water for injection  
 
Ingredients  Quantity per Vial  
Andexanet  200 mg  
Tris (Tromethamine)  6.52 mg  
Tris HCl  7.33 mg  
L-Arginine Hydrochloride  94.8 mg  
Sucrose  200 mg  
Mannitol  500 mg  
Polysorbate 80  2.0 mg  
Sterile Water For Injection  QS to 20 mL (removed  during 
lyophilization process)  
HCl = hydrogen chloride; QS  = Quantum Sufficiat  [Latin: as much as will suffice]  
6.2. Dosing and Administration  
Andexanet will be administered as an IV bolus, immediately followed by a continuous infusion.  
There are two possible dosing regimens as described in  Table  3.  Time -points and windows for 
treatment procedures are outlined in  Appendix A .  Initiation of andexanet dosing should occur no 
later than 30 minutes after randomization and preferably within 2 hours of the baseline brain 
imaging scan. To accommodate dosing within 2 hours of the baseline scan closest to 
randomization, reconstitution of andexanet prior to randomization will be allowed. 
Table  3: Dosing Paradigm for Andexanet 
Dose  Initial IV Bolus  Follow -on IV Infusion  
Low  400 mg at a target rate of 30 mg/min  
for ~15 minutes  480 mg at a target rate of 4 mg/min for 
120 minutes  
High  800 mg at a target rate of 30 mg/min  
for up to ~30 minutes  960 mg at a target rate of 8 mg/min for 
120 minutes  
IV = intravenous  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 47 The decision to administer a low or high dose will be governed by the dose regimens in Table  4: 
Table  4: Andexanet Dose Regimens 
FXa Inhibitor  FXa Inhibitor 
Last Dose a Timing of FXa Inhibitor Last Dose before Andexanet Initiation  
< 8 Hours  ≥ 8 Hours  > 15 Hours or 
Unknown b 
Rivaroxaban  10 mg  Low Dose  Low Dose  High Dose  
> 10 mg  High Dose  
Apixaban  ≤ 5 mg  Low Dose  
> 5 mg  High Dose  
Edoxaban  30 mg  Low Dose  
> 30 mg  High Dose  
a. This represents the last dose taken by the patient, not the total daily dose.  
b. ONLY if 1) the local anti- fXa activity > 100 ng/mL for direct fXa inhibitors (apixaban, rivaroxaban 
or edoxaban), and 2) the local anti- fXa activity level  is obtained within 2 hours prior to consent and performed 
as per standard of care . 
6.3. Storage 
The labele d storage cond ition for andexane t is refrigerated, (i.e., 2-8°C) .  The  temperature of the 
medicine re frigerat or shou ld be mon itored with an electronic temperature monit oring devi ce. 
The Investigator (or his or her designee) is required to confirm that appropriate temperature 
conditions were maintained during transit of the drug.  Any temperature excursions and 
resolution of any temperature excursions prior to drug use must be reported within one business 
day.  Any product complaints must also be re ported within one business day.  Please refer to the 
Pharmacy Manual for details.  
6.4. Drug Account ability and Com plian ce 
The dispensing ph armacist or designated qua lified individua l will write at least  the date 
dispensed, dose di spensed, and the patient’ s identifi cation number on the Drug A ccountability 
Sourc e Documents.  Al l medi cation supplied w ill be accounted for on the Drug 
Accountability Record. 
All partially used or unused drug supp lies will either be  destroyed a t the site in ac cordance w ith 
approved wr itten site pro cedure s or returned to the Sponsor  or its designee only after written 
authorization is obta ined from the Sponsor  or its designees.  The Inve stigator w ill maintain a 
record of the amount and date s when unus ed supplie s were either destroyed or returned to the 
Sponsor .  All records w ill be retained as noted i n Section 12.5  Retention of Data.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 48 7.0 PRIOR AND CONCOMIT ANT ME DICATIO NS AND TREATMENTS 
7.1. Prior Medi cation s and Treatmen ts 
Section  4.1 and Section  4.2 describe restric tions on pr ior m edications and trea tments. 
Platelets and PRBCs are allowed at any time prior to screening.  
The followed are not allowed within 7 days prior to consent: 
• Vitamin K Antagonist (VKA) (e.g., warfarin)  
• Dabigatran  
• Prothrombin Complex Concentrate products (PCC, e.g., KCentra®) or recombinant 
factor VIIa (rfVIIa) (e.g., NovoSeven®), or anti-inhibitor coagulant complex (e.g., 
FEIBA®), FFP, and whole blood 
Past use of commercial andexanet is not permitted, and treatment with an investigational drug 
< 30 days prior to consent is not permitted.  
7.2. Concomitant Medi cations, Hemostatic, and Pro-coagulant Treatments 
The use of concomitant medications and treatments, including surgeries, is summarized in 
Table  5 and detailed in the subsections below. 
Table  5: Allowed Use of Concomitant Medications and Treatments  
Concomitant Medication and Treatments  Allowed Use  
Anticoagulants (e.g., direct thrombin 
inhibitors, FXa inhibitors, vitamin -K 
antagonists) and Antiplatelet Drugs (e.g., 
prasugrel, ticagrelor, clopidogrel, aspirin, 
NSAIDs)  • For both treatment groups, can be restarted at any time based on clinical judgment.  
Platelets and PRBCs  • Patients in both groups may receive platelets and/or PRBC 
transfusions at any time.  
• Use of platelets or red blood cells will not have any bearing on hemostatic efficacy.  
Pro-Coagulant Blood Products (pro -
coagulant factor infusions [e.g., 3 - or 
4-factor PCC/activated PCC, recombinant 
fVIIa, plasma, FFP, FEIBA®], and whole 
blood) • For patients randomized to usual care treatment, blood 
products may be administered within the initial 3 -hour 
treatment window post -randomization per 
institutional/local practices and/or guidelines.  
• For patients randomized to andexanet, blood products may be administered if a patient is found to have hematoma 
expansion.  
• For both treatment groups, administration of blood 
products between 3 hours post -randomization and the 
12-hour hemostatic efficacy e valuation will result in the 
patient being considered to have poor/none hemostatic 
efficacy .  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 49 Table  5: Allowed Use of Concomitant Medications and Treatments  
Concomitant Medication and Treatments  Allowed Use  
• Misadministration of procoagulant blood products contrary 
to treatment allocation within 3 hours post -randomization 
(including andexanet in usual care arm) will b e reviewed 
by EAC.  
Hemostatic Agents (systemic 
anti-fibrinolytic [e.g., aminocaproic acid] 
and other systemic hemostatic agents)  • For patients randomized to usual care treatment, systemic 
hemostatic agents may be administered per institutional/local practi ces and/or guidelines.  
• For patients randomized to andexanet, local hemostatic 
agents and topical vasoconstrictors may be administered as 
clinically appropriate.  
• For both treatment groups, administration of systemic hemostatic agents (with the exception of tranexamic acid) 
between 3 hours post -randomization and the 12 -hour 
hemostatic efficacy evaluation will result in the patient being considered to have poor/none hemostatic efficacy.  
• Administration of hemostatic agents within 3 hours post-randomization wil l be reviewed by EAC.  
Diagnostic and Therapeutic Procedures, including Surgeries, for Bleeding (including 
Burr holes intended for hematoma 
expansion)  • For both treatment groups, planned minimally invasive procedures not directly related to treatment of the 
intracranial bleeding (e.g., endoscopy, bronchoscopy, central lines) may be performed without restrictions as deemed clinically appropriate.  In addition, Burr holes are 
allowed at any time if they are indicated for placement of 
an intracr anial pressure monitor, and not anticipated to 
drain any portion of hematoma volume.  
• For both treatment groups, performance of an unplanned rescue surgery or interventional procedure to treat the index hematoma in the event of clinical deterioration 
betwee n 3 hours post -randomization and the 12 -hour 
hemostatic efficacy evaluation will result in the patient 
being considered to have poor/none hemostatic efficacy.  
• Unplanned rescue procedures or surgery which could impact hematoma volume will be reviewed by EA C. 
• For both treatment groups, performance of a surgery or interventional procedure to treat the index hematoma or could impact hematoma volume within 3 hours post-randomization will be reviewed by EAC.  
EAC = Endpoint Adjudication Committee; FEIBA  = factor  eight inhibitor bypass activity; FFP  = fresh frozen 
plasma; fVIIa  = factor VIIa; FXa  = factor Xa; NSAIDS = nonsteroidal anti- inflammatory drugs; 
PCC = prothrombin complex concentrate; PRBC = packed red blood cell  
7.2.1. Anticoagulants and Antiplatelet Drugs  
Investigators may choose to re- start anticoagulants or antiplatelet drugs ( including, but not 
limited to prasugrel, ticagrelor, clopidogrel, asp irin, and Non-Steroidal Anti- Inflammatory 
Drugs [ NSAI Ds]) at any time based on clinical judgment.  If anticoagulants or antiplatelet agents 
are restarted during the study, the date, time, and agent(s) used should be recorded on the CRFs. 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 50 7.2.2. Blood Products  
To maintain uniformity in transfusion practices across study participants, it is strongly suggested 
that the trigger for PRBC transfusion is a hemoglobin ≤ 8.0 g/dL (± 1 g/dL).  The hemoglobin 
triggering a transfusion, clinical stability factors (e.g., shock) influencing the decision to transfuse, as well as number of units transfused should be recorded on the CRFs.  
For both treatment groups, transfusion of platelets and/or PRBCs may be performed at any time without any bearing on the primary efficacy endpoint. 
Use and timing of blood products, including number of units transfused and the date and time of 
administration should be recorded on the CRFs. 
7.2.3. Procoagulant Blood Products  
For patients randomized to usual care treatment, pro -coagulant factor infusions (e.g., 3- or 
4-factor PCC/activated PCC, rfVIIa, plasma, FFP, FEIBA®), and/or whole blood may be 
administered within the initial 3 -hour treatment window post-randomization according to 
standard institutional/local practices and/or guidelines.  If a patient is randomized to andexanet, 
Investigators may consider using pro- coagulant factor infusions, as listed above, if a patient is 
found to have hematoma expansion (i.e., a > 35% increase in volume from baseline) on either a protocol-driven or clinically- indicated scan.  Otherwise, treatment with the above products is 
strongly discouraged, though not prohibited, during the entire 30-day observation period. 
For both treatment groups, use of pro-coagulant factor infusions (e.g., 3- or 4- factor 
PCC/activated PCC, rfVIIa, plasma, FFP, FEIBA
®) and/or whole blood between 3 hours after 
randomization and the 12-hour hemostatic efficacy evaluation measurements will result in the 
patient being considered to have poor/none hemostatic efficacy. 
Misadministration of procoagulant blood products contrary to treatment allocation within 3 hours 
post-randomization (including andexa net in usual care arm) will be reviewed by EAC.  
7.2.4. Hemostatic Agents  
For patients randomized to usual care treatment, systemic anti -fibrinolytic (e.g., aminocaproic 
acid) and other systemic hemostatic agents may be administered according to standard institutional/local practices and/or  guidelines.  If a patient is randomized to andexanet, 
Investigators may consider using hemostatic agents, as listed above, if a patient is found to have hematoma expansion as delineated in Section  7.4.  Otherwise, treatment with these agents is 
strongly discouraged, though not prohibited, during the entire 30-day observation period. 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 51 Similarly, for patients randomized to usu al care treatment, local hemostatic agents 
(e.g., microfibrillar collagen and chitosan-containing products) and topical vasoconstrictors 
(e.g., epinephrine) may be used as deemed clinically appropriate.  For patients randomized to 
andexanet, Investigators may consider using local hemostatic agents if a patient is found to have 
hematoma expansion.  Otherwise, treatment with these agents is strongly discouraged, though not prohibited, during the entire 30-day observation period. 
For both treatment groups, use of systemic hemostatic agents (with the exception of tranexamic 
acid) between 3 hours after randomization and the 12-hour hemostatic efficacy evaluation 
measurements will result in the patient being considered to have poor/none hemostatic efficacy. 
Admini stration of hemostatic agents within 3 hours post randomization will be reviewed by 
EAC.  
Use and timing of hemostatic agents, their dose, and the date and time of administration should 
be recorded on the CRFs. 
7.3. Diagnostic and Therapeutic Procedures for Bleeding  
Patients scheduled at the time of randomization to undergo surgery or hematoma drainage 
procedures (including Burr holes intended for hematoma evacuation) within 12 hours after 
randomization are excluded from the study, though unpla nned rescue procedures of this nature 
may be carried out post- randomization (see  Section  4.2 for Exclusion Criteria).  
Burr holes planned within 12 hours after randomization are allowed if they are indicated for 
placement of an intracranial pressure monitor, and not anticipated to drain any portion of 
hematoma volume.  In addition, planned minimally invasive procedures not directly related to 
treatment of the intracranial bleeding (e.g.,  endoscopy, bronchoscopy, central lines— see 
Appendix G ) may be performed without restrictions as deemed clinically appropriate.  
Through the period of the primary efficacy assessment (12 hours after randomization), Investigators will be requested to pursue additional brain imaging (e.g., CT, MRI, cerebral 
angiogram) to evaluate for hematoma expansion (i.e., continued bleeding or re- bleeding) if 
clinically indicated.  Patients will be re -scanned if they have a clinically significant new or 
worsening, focal or global, neurologic deficit relative to baseline (e.g., an increase from baseline 
in the NIHSS score of 5 or greater), that is not readily explainable by an alternate etiology 
(e.g., sedatives, infection).  The new neurologic deficit can be discovered at any time following 
initial treatment through 12 hours after randomization.  In addition, Investigators will be allowed 
to pursue additional brain imaging at any time for any medically appropriate reason.  
For both treatment groups, performance of an unplanned rescue surgery or interventional procedure specifical ly indicated to treat the index hematoma in the event of clinical deterioration 
between 3  hours after randomization and the 12- hour hemostatic efficacy evaluation will result 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 52 in the patient being considered to have poor/none hemostatic efficacy. Unplanned rescue 
procedures or surgery which could impact hematoma volume will be reviewed by EAC. 
For both treatment groups, performance of an unplanned rescue surgery or interventional 
procedure to treat the index hematoma or could impact hematoma volume within 3 hours 
post-randomization will be reviewed by EAC. 
The use and timing of procedures for diagnosis and management of bleeding should be recorded 
on the CRFs. 
7.4. Continued Bleeding, Re -bleeding, and Rescue Therapy  
In this study, there is potential for patients to experience continued bleeding and/or re-bleeding 
after therapy (be it usual care or andexanet).  That said, because they represent the two potential 
mechanisms for hematoma expansion, continuous bleeding and re-bleeding should be considered 
within the br oader scope of hematoma expansion.  That is, patients with continuous bleeding and 
patients with re -bleeding represent subsets of patients with hematoma expansion.  Therefore, 
when considering the use of rescue therapy for continued bleeding or re-bleeding, Investigators 
should consider whether the patient has evidence of hematoma expansion (defined as any 
increase from baseline in hematoma volume greater than 35%).  
For all patients, while Investigators are strongly encouraged to perform diagnostic imaging if continued or recurrent bleeding is suspected, any therapy (other than andexanet) may be used at 
any time to address continued or recurrent bleeding.  No andexanet dosing (for the usual care 
group) or re -dosing (for the andexanet group) is allowed. 
For a ll patients, any blood product (excluding PRBCs and platelets), pro- coagulant factor 
infusions, or systemic hemostatic therapy (except tranexamic acid) specifically intended to 
address continued or recurrent bleeding (as listed in Section  7.2.2 and Section 7.2.4), initiated at 
least 3  hours afte r randomization but before the 12 -hour hemostatic efficacy assessment, will be 
considered rescue therapy.  Any patient receiving such systemic rescue therapy will be considered a treatment failure (i.e., poor/none hemostatic efficacy).  
Additionally, any unplanned rescue surgical procedure specifically intended to treat the hematoma at any time between 3 hours post -randomization and the 12- hour hemostatic efficacy 
evaluation measurements will result in the patient being considered to have poor/none hemostati c 
efficacy.  
7.5. Infusion Reactions  
As discussed in the IB, mild to moderate infusion reactions were reported in healthy subjects who received andexanet and rarely occurred in bleeding patients who were treated in a 
Phase 3b/4 study.  These infusion reactions have generally resolved without interruption of the 
infusion or medical intervention.  In the event that the Investigator determines that intervention is 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 53 warranted, consideration may be given to slowing the infusion rate, or temporary interruption of 
the dose followed by re- starting the infusion at a slower infusion rate.  Treatment with 
diphenhydramine may also be considered. 
7.6. Thrombotic Events  
Patient s will be  monito red carefully for signs and symptom s of TEs (i.e., strokes, TIAs, MIs, 
DVTs, PEs, arterial systemic embolisms) throughout the cour se of  the study.  In the event tha t 
the Inves tigator susp ects a TE, it is expected that an  appropriate evalua tion will be  performed 
(e.g., head CT, electrocardiogram [ECG]/cardiac enzymes, lower extremity ult rasound, 
pulmonar y vascular  imaging).  Investigators are requested to consult the guidance listed in 
Appendix K  when considering whether an event should be submitted for adjudication.  Ongoing 
periodic review of AEs during the conduct phase of the study, assessing for potential TEs to be 
submitted for adjudication, will also be conducted by the Sponsor. 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 54 8.0 ADV ERSE EVE NT REPORTING 
8.1. Adverse Even t Definitions 
According to the ICH guideline for GCP, an AE is any untoward medical occurrence in a clinical 
investigation subject administered a pharmaceutical product, regardless of causal attribution to 
study treatment or procedure.  An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.  For the purposes of this study, a Treatment- Emergent AE (TEAE) is 
one that occurs at any time following treatment initiation.  
Example s of AEs includ e: 
• Any tr eatm ent e mergent signs and symptom s (events that are marked by a change 
from the pa tient’s baseline/entry status [e.g., an inc rease in sever ity or frequency of 
pre-existing abnorma lity or di sorder or recurrence of an intermittent medical condition 
not present at baseline]).  
• All reactions from study drug, abuse of drug, withdrawal phenomena, sensitivity or 
toxicity to study drug. 
• Any complication or injury resulting from a study -specific procedure 
(e.g., thrombophlebitis from an IV line). 
• Apparently unrelated illne sses. 
• Injuries or a ccident s. 
• Extensi ons or  exacer bations of symptomatology, subj ective pa tient-repor ted events, 
new clinica lly signifi cant abnorma lities in c linical labora tory, physiolo gical testing, or 
phys ical exa mination. 
• Abnorm
 al labora tory fi ndings conside red by t he Inves tigator to be c linically 
signifi cant,  represent a worsening from b aseline, and meet any of the below- listed 
criteria  should be reported a s an AE.  An abnorm al labora tory value shoul d be 
recorded a s an AE  if it: 
○ Is associated with clinical signs or symptoms,  
○ Requires an intervention,  
○ Results in an SAE, or 
○ Results in study discontinuation. 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 55 When recording an AE resulting fr om a labora tory abnorma lity, the resulting medi cal conditi on, 
if known, rather than the abnorma lity itself should be recorded (e.g., record “anemia” rather than 
“low h emoglobin”) . 
When a unifying dia gnosi s has been made tha t account s for sever al possible signs and/or 
symptoms, the unifying diagnosi s shou ld be se lected a s the A E term.  For example, the 
combina tion of genera l malaise, mild fe ver, headache, and rhin itis should be des cribed a s “upper 
respiratory syndrome ” if thi s diagnosi s has been made, rather than reporting the individua l 
symptoms a s separate event s. 
8.1.1. Study -specific Exceptions to Adverse Event/Serious Adverse Event Reporting  
For the purposes of this trial, hematoma expansion or intracerebral bleeding and associated 
neurological deterioration that occurs within the first 12  hours post- randomization will not be 
regarded as an AE or SAE except when there is evidence suggesting a causal relationship between the drug and the event.  Such events will be captured on the electronic Case Report 
Form (eCRF) and in the database as outcomes only; they will also be w aived from unblinding 
and exempt from expedited reporting. 
8.2. Serious Adverse Event Definition 
An SA E is any A E, occurring regar dless of causa lity, that: 
• Results in death.  
• Is life -threatening.  Life-threatening means that, in the opinion of the Investigator or 
Study Sponsor, the patient/subject was at immediate risk of death from the reaction as 
it occurred, (i.e., it does not include a reaction that hypothetically might have caused death had it occurred in a more severe form). 
• Requires inpatient  hospitalization or prolongation of existing hospitalization.  
Hospitalization admissions and/or surgical operations scheduled to occur during the study period, but planned before the signing of the ICF, are not considered AEs if the illness or disease exi sted before the patient was enrolled in the trial, provided that it 
did not deteriorate in an unexpected manner during the trial (e.g., surgery performed earlier than  planned). 
• Results in persistent or significant disability/incapacity.  Disability is defi ned as a 
substantial disruption of a person’s ability to conduct normal life functions. 
• Is a congenital anomaly/birth defect.  
• Is an important medical event.  An important medical event is an event that may not result in death, be life-threatening, or require hospitalization but may be considered an SAE when, based upon appropriate medical judgment, it may jeopardize the patient/subject and may require medical or surgical intervention to prevent one of the 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 56 outcomes listed in the definitions for SAEs.  Exampl es of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at 
home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse. 
A distinction should be made between the t erms
  “serious” and “sev ere” since they are not 
synonymous.  The term “sever e” is often used to des cribe the intensity (sev erity) of a sp ecific 
event (a s in mild, moder ate, or severe MI; the event it self, ho wever, may be of relatively minor 
medic al signif icance ( such as sever e headache) .  This is not the same as “serious,” which i s 
based on patient/eve nt ou tcome or action cr iteria usua lly associated w ith event s that pose  a thr eat 
to a patient’ s life or functioning.  A sev ere AE does not necess arily n eed to be considere d 
serious.  For ex ample, per sistent na usea of several hours’ dura tion ma y be considered severe 
nausea but not an SA E if the event does not m eet the serious criteria.  On the other hand, a str oke 
resulting i n only a minor degree of disability may b e considere d mil d but would be def ined as an 
SAE based on the above noted s erious criteria. 
8.2.1. Regulatory Reporting Requirements for Serious Adverse Events 
• The Investigator must notify the Sponsor of an SAE within 24 hours of the first awareness of the event.  
• The Sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study drug under clinical investigation.  The Sponsor will comply with country -specific regulatory 
requirements relating to safety reporting to the regulatory authority, Institutional Review Board  (IRB)/ Independent Ethics Committee (IEC), and Investigators. 
• The Council for International Organizations of Medical Sciences (CIOMS) or 
MedWatch reports must be prepared for suspected unexpected serious adverse 
reactions  (SUSARs) (Section  8.3) according to local regulatory requirements and 
Sponsor policy and forwarded to Investigators as necessary.  The Sponsor’s 
procedures for the reporting of SUSARs are in accordance with United States Title 21 Code of Federal Regulations (CFR)312.32 and European Union Clinical Trial Directive 2001/20/EC and the associated detailed guidance documents or national 
regulatory requirements in participating countries as well as IRBs/IECs where applicable. 
• An Investigator who receives an Investigator safety report describing an SAE or other specific safety information (e.g., summary or listing of SAEs) from the Sponsor will review and acknowledge the report and notify the IRB/IEC, if appropriate, according to local requirements.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 57 8.3. Suspected Unexpected Serious Adverse Reactions 
A SUSAR is an event that is assessed as serious by the Investigator and/or the Sponsor that is not 
listed in the Reference Safety Information of the IB and has been assessed as having at least a 
reasonable possibility of being related to the investigational medicinal pr oduct by the 
Investigator and/or the Sponsor.  
The Sponsor has procedures that will be followed for the recording, medical assessment, and 
expedited reporting of SUSARs that are consistent with global regulations, legislation, and 
guidance documents. 
SUSARs will undergo expedited reporting to the national regulatory authorities, IRBs/IECs, and 
Investigators following local regulatory reporting requirements where applicable.  The Sponsor 
is required to take the following actions:  
• In the case of SUSARs with an outcome of death or that are life -threatening, the 
Sponsor is required to report the event within 7 days.  SUSARs with any of the other 
outcomes are required to be reported to regulators within 15 days.  
• Inform all Investigators of the SUS AR. 
8.4. Adverse Events of Special In terest  
Thrombotic or embolic events of any severity ar e AESI and should be reported as non- serious 
AEs or as SAEs (if appropriate) w ithin 24 hour s after the I nvestigat or is made aware of them, as 
described in Section  8.8. 
The Investigator will assess relationship of the AESI to andexanet as described in Section  8.5. In 
addition, the DSMB will periodically consider whether the occurrence of AESIs (whether related 
or not) warrant changes to the study (see Section 10.6.2 and the DSMB Charter). 
8.5. Assessment of Causal Relations hip 
The Investigator should use their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether or not an AE is 
considered to be related  to the randomized treatment (andexanet or usual care).  For each 
AE/SAE, the Investigator must document in the medical notes that they have reviewed the AE/SAE and have provided an assessment of causality.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 58 The following categories should be used in the causality assessment of suspected 
adverse reactions:  
Related  
The AE: 
• Follows a reasonable temporal sequenc e from the time the randomized treatment was 
administered; and/or  
• Follows a known response pattern to the randomized treatment; and 
• Does not have a likely alternative etiology. 
Unrelated   
The AE: 
• Does not follow a reasonable temporal sequence from the time the randomized 
treatment was administered; and  
• Was most likely produced by other factors, such as the patient’s clinical state, therapeutic intervention, or concomitant therapy; or 
•  Was clearly and incontrovertibly due only to extraneous causes (e.g., the patient’s clinical state, therapeutic intervention other than bleeding control, or concomitant therapy other than the randomized treatment) and does not meet the criteria listed above under “Related.”  
An A E with causal relationship not initi ally dete rmin ed w ill require urgent f ollow-up to a ssign 
causa lity.  Additionally, lack of efficacy does not necessarily constitute relatedness to the 
randomized therapy.  
8.6. Assessment of Severity 
The Investigator must d etermine the severity of the event a ccording to t he criteria bel ow and the 
Inves tigator’s clinical ju dgment.  Severity des cribes the inte nsity of the AE.  Events th at change 
severity during the cour se of foll ow-up shoul d be recorded based on their highest severity grade. 
Mild 
Awareness of sign or symptom, but easily to lerated 
Mode rate Discomfor t enough to cause int erference with norma l daily ac tivities 
Severe  Inability t o perform norma l daily ac tivities 
 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 59 8.7. Adverse Even t Reporting  
For all patients, the  AE reporting period st arts with the signing of the ICF and conti nues through 
the Day 30 Follow-up visit.  For patients who have a positive anti-andexanet antibody response 
at the Day  30 visit, the AE reporting period will extend through their Day 120 follow-up visit. 
Patients in this study who experienc e an andexanet -related AE or SAE will be followed until the 
AE or SAE is resolved or until a new stable baseline is established, even if this occurs after the 
Day 30 Follow -up visit.  A ll AEs spontaneously reported by the pa tient a nd/or in response to an 
open ques tion from study per sonne l or revealed by obs ervation, physi cal examination, or  other 
diagnos tic procedure s will be recorded and reported on the appropriate CRF through the Day 30 
Follow -up visit . 
8.8. Reporting of Serious Adverse Even ts and Ad verse Even ts of Spec ial Interest  
After informed consent has been signed but prior to initiation of study treatment, only SAEs 
caused by a protocol-mandated intervention (e.g., invasive procedures such as biopsies, discontinuation of medications) should be reported.  After initiation of study treatment , all AEs, 
regardless of relationship to study treatment, will be reported until 30 days after the last dose of the study treatment.  After this reporting period, the Investigator is not required to actively 
monitor patients for AEs; however, the Sponsor should be notified if the Investigator becomes 
aware of any post -study SAEs that are believed to be related to prior study treatment.  
All SAEs and AESIs (see Section  8.4) must be reported by the Investig ator by sending the SAE 
Form and any per tinent source document s and recording the SAE on the A E CRF, within 
24 hour s from the point in tim e when the Inves tigator bec omes aware of the SA E.  Submiss ion 
of an SAE should not be w ithheld even if complete informa tion about the event is not ava ilable 
at the time  of the initial report.  Any follow-up informa tion o n a previously reported SA E or 
AESI shou ld be sent promptly by t he Inves tigator w ithin 24 hour s from the poi nt in time when 
the Inves tigator bec omes aware of it), or a s reques ted by the Sponsor  or its designee .   
The Sponsor will immediately notify the Investigator about important safety or toxicology 
informatio
n, including neutralizing antibodies against FX or FXa identified in a patient treated 
with andexanet in any clinical study, as it becomes available.  It is the responsibility of the 
Investigator to promptly notify the IRB/IEC about ne w and relevant safety information regarding 
the study drug, including serious adverse drug reactions (implied causal relationship to study treatment) involving risk to human subjects, in accordance with the applicable policies.  Certain 
countries (e.g., the Netherlands) require the Sponsor to notify the IRB/IEC about new and relevant 
safety information regarding the study drug, including serious adverse drug reactions involving 
risk to human subjects.  An unexpected event is one that is not listed by nature  or severity in the 
Reference Safety Information.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 60 8.9. Contraception  
Andexanet is not expected to have reproductive or developmental toxicity based on the following:  
1) andexanet is intended for single -dose administration and, therefore, has limited potential for 
reproductive or developmental toxicity; 2) andexanet is a biotechnology- derived protein that is a 
modification of an endogenous protein in the coagulation cascade (FXa); 3) andexanet has a very 
short half -life (1 - to 2-hour effective half -life); and 4) andexanet was designed as a universal 
antidote for FXa inhibitors, which are prescribed primarily in elderly patient populations that are not of reproductive capacity.  Andexanet is not expected to interact with hormone contraception.  
Nevertheless, one of the following highly effective birth control methods is recommended for female patients of childbearing potential for the entire duration of the trial and for at least 1  month 
after study drug administration:  
• Combined (estrogen- and progestogen-containing) hormonal contraception associated 
with inhibition of ovulation: 
○ Oral 
○ Intravaginal  
○ Transdermal  
• Progestogen-only hormonal contraception associated with inhibition of ovulation: 
○ Oral 
○ Injectable  
○ Implantable  
• Intrauterine device  
• Intrauterin e hormone -releasing system  
• Bilateral tubal occlusion  
• Successfully vasectomized partner  
• Sexual abstinence 
Male patients with female sexual partners who are pregnant or of childbearing potential must use 
one acceptable method of contraception, including a ba rrier method (e.g., condom), for the entire 
duration of the study and for at least 1  month following study drug administration.  Also, male 
patients must refrain from attempting to father a child or donating sperm for 1  month following 
study drug administr ation.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, 
post-ovulation methods) and withdrawal are not acceptable methods of contraception.  
Acceptable birth control methods are those that result in a failure rate of more than 1% per year. These methods include progestogen-only oral hormonal contraception, where inhibition of 
ovulation is not the primary mode of action; male or female condom with or without spermicide 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 61 cap; and diaphragm or sponge with spermicide.  A combination of male condom with either cap, 
diaphragm, or sponge with spermicide (double barrier methods) are also considered acceptable 
but are not highly effective birth control methods. 
8.9.1. Pregnancy Reporting  
If a woman who is a study patient becomes pregnant or a woman suspects she is pregnant from a male study patient, the Investigator should be informed immediately.  The Sponsor must, in turn, 
also be notified by the Investigator immediately (no more than 24 hours after learning of the 
pregnancy) by completing a Pregnancy CRF and a Pregnancy/Breastfeeding Reporting and 
Outcome form.  In the event a female partner of a male patient is pregnant or suspects she is 
pregnant by the male patient, the male patient will be advised by the study Investigator to have his 
pregnant partner inform her treating physician immediately.  The pregnancy must be followed up 
through delivery or other fetal outcome and information reported on a Pregnancy Follow -up form.  
For any abnormal fetal outcome, including congenital anomaly or birth def ect, spontaneous or 
therapeutic abortion, stillbirth, pre -mature birth, or other outcome other than live normal birth, the 
Investigator should immediately report to the Sponsor the abnormal fetal outcome on an SAE form.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 62 9.0 STUDY ASSE SSM ENTS  
Details on t he co llection, processing, stora ge, and shipment of sampl es are contained in the 
Laboratory Manual. 
9.1. Efficacy Assessmen ts 
9.1.1. Effective Hemostasis  
Effective hemostasis is a composite endpoint based on image evaluation (CT or MRI), NIHSS 
score, and use of rescue therapy.  Imaging is to be performed at baseline and approximately 
12 hours post-randomization, and should utilize a consistent imaging modality for both time-points to minimize technical discrepancy (i.e., CT or MRI scan).  However, additional 
imaging may  be performed at any time during the study per Investigator discretion and should be 
considered in the case of clinical deterioration.  NIHSS evaluation (blinded or unblinded) to 
inform hemostatic efficacy will be performed at baseline (prior to randomization) and at 2 hours, 
3 hours, 6 hours, and 72 hours post- randomization.  Blinded NIHSS evaluation will occur at 
12 hours and 24 hours post-randomization to minimize bias.  As with brain imaging, additional assessments may be performed at any time.  Use of rescue therapy (including procedures 
intended to treat the hematoma), as defined in Section  7.2, Section  7.3, and Section  7.4, between 
3 hours and 12 hours following randomization will be consider ed a treatment failure (i.e., 
poor/none hemostatic efficacy). 
9.1.2. Anti-f Xa Act ivity 
Anti-fXa activity w ill be mea sured from pla sma sample s to a ssess the antic oagula nt status of 
FXa inhibitors using a modified chromogenic a ssay perf ormed a t a Cent ral Laboratory.  Anti- fXa 
activity will be evaluated at baseline, and at 1 - and 2 -hours post-randomization. 
9.1.3. Thrombin Generation  
Thrombin generation w ill be mea sured from pla sma samples to a ssess the antic oagulant ef fect of 
FXa inhibitors .  Tissue factor -dependent t hrombin genera tion w ill be performed a t a Cent ral 
Laboratory.  Five parameters related to thrombin generation are measured:  Endogenous Thrombin Potential (ETP), peak height, time to peak height, lag time, and velocity index.  ETP is 
prospectively identified as the primary measure for thrombin generation.  Thrombin generation 
will be assessed at baseline, and at 1 - and 12-hours post- randomization.  
9.1.4. Glasgow Coma Scale (GCS) Score 
GCS evaluation (blinded or unblinded) will be performed at baseline (prior to randomization) and at 2 hours, 3 hours, 6 hours and 72 hours post-randomization.  Blinded GCS evaluation will 
occur at 12 hours and 24 hours post-randomization. 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 63 9.1.5. Modified Rankin Scale  
An mRS score will be obtained at baseline (pre-morbid), at 30 days post- randomization or at the 
Early Termination visit.  If the baseline mRS is unavailable during screening, the mRS can be 
collected from either the patient, relative, care giver, or LAR at a post -randomization timepoint 
as long a s the mRS reflects the patient’s pre -morbid (i.e., pre- ICrH) neurological status.  The 
pre-morbid mRS score should reflect the patient’s neurological status prior to acute illness.  The 
utility -weighted mRS (uw -mRS) is a quality -of-life measure ensuring t hat the mRS score reflects 
both treatment effect and patient perception.  In the uw-mRS, utilities based on the EuroQol 
Group 5- Dimension (EQ -5D) questionnaire values are assigned to the mRS health states.  
9.1.6. EQ-5D (EuroQol- 5 Dimension)  
A five -dimension heal th-related quality of life measure for clinical and economic appraisal will 
be obtained at 30 days post- randomization or at the Early Termination visit.  
9.2. Safety Assessme nts (other than Adverse Events) 
9.2.1. Vital Signs, Height, and Weight  
Vital signs include temp erature, SBP, Diastolic Blood Pressure (DBP), Heart Rate, and 
Respiratory Rate.  
Height and weight will be recorded at screening and baseline. If it is not possible to measure 
height or weight, a reported height or weight, or a recent height or weight from the medical 
record is acceptable.  
9.2.2. Clinical Laboratory Test ing 
Blood specimens for rout ine chemistry and hema tology w ill be  obta ined at selected time -points 
(see Appendix A ). 
The following a ssays will be performed a t the Local Laborato ry (as available) : 
• Hematology:  hemoglobin, hematocrit, White Blood Cell (WBC) count, platelet 
count, WBC differential  
• Coagulation:  International Normalized Ratio (INR) 
• Serum Chemistry:  sodium, potassium, chloride, carbon dioxide (bicarbonate), glucose, blood urea nitrogen, creatinine, aspartate aminotransferase, alanine aminotransferase, albumin, alkaline p hosphatase, calcium, phosphorus, and total, 
direct, and indirect bilirubin 
• Serum or urine pregnancy test (in females of childbearing potential; see  Appendix J ) 
• Anti-fXa activity (for patients treated with an oral FXa inhibitor > 15 hours prior to 
randomization or unknown time of last dose).  Note:  Measurements of anti- fXa 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 64 activity after initiation  of andexanet are discouraged because of assay interference 
with andexanet.  Please consult the Laboratory Manual for further details.  
Local Labora tory assays of hematology, coagulation, and serum chemistry are not required for 
the purpose of eligibility. However, complete panels should not be missed at screening/baseline 
because these assays inform the investigator of suitability of the patient for the study (e.g., 
multiorgan failure, metabolic or hematological abnormalities).   
The following assays will be performed at a Central Laboratory:  
• Anti-fXa activity (Note:  evaluation of the secondary efficacy endpoint will use only 
central, and not local, anti- fXa activity)  
• Antibodies to FX, FXa, and andexanet 
• Neutralizing antibodies to FX, FXa, and andexanet 
• Thrombin generation 
The multiple samples collected within a narrow window of time (±15  min) from baseline through 
to the first 2  to 3 hours are critical for the Central Lab’s assessment of andexanet activity.   
9.2.2.1. Exploratory Biomarker Assessments  
Samples for  tissue factor pathway inhibitor (TFPI) activity or other future exploratory biomarker 
research will also be obtained at selected time -points (see  Appendix A ). 
TFPI, an endogenous inhibitor of fXa and known to interact with andexanet, will be measured 
using Antichrome®-TFPI Chromogenic assay at a Central Laboratory. TFPI will be evaluated at 
basel ine, 1- , 2-, and 12-hours post-randomization and at the 30 day follow-up visit. 
 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 65 10.0 STATIST ICAL CONSIDE RATIONS AND DAT A ANALYS IS 
The Study Objectives and Study Design are des cribed i n Section  2.0 and S ection 3.1, 
respectively.  The information in this section is a summary of the planned statistical analyses. 
10.1. General Cons iderations 
During the conduct of the study, the Sponsor and Investigators will be blinded to the aggregated 
efficacy and safety summaries.  Also, all unblinded analyses that are required to support the 
DSMB will be performed by an independent unblinded statistician.  These analyses will be 
performed under the direction of the DSMB according to the Statistical Analysis Plan (SAP) and 
the DSMB Charter.  The results of these unblinded analyses will not be available to the Sponsor 
or Investigators until after database lock, unless the DSMB recommends early termination of the 
trial. 
The safety interim analyses will follow the same procedures as the efficacy interim analysis (see Section 10.7 ), with the Sponsor rema ining blinded to the results of these analyses unless the 
DSMB recommends stopping the trial early.  
Once the study is complete and the final database lock is performed, the study will be fully 
unblinded and final analyses will be performed. 
All efficacy hy pothesis tests will be 2 -sided and performed at the 0.05 significance level.  
Adjustments for the overall type I error for the planned interim efficacy analysis are described in 
Section  10.7 . 
It is anticipated that sta tistica l summar ies will be perf orme d usi ng SAS Version 9.2 
(SAS I nstitute, Inc., Ca ry, NC, USA) or high er.  Additi onal software may be used for the 
produc tion of gra phics and for statistical methodology not available in SAS.  
All efficacy and safety endpoint parameters will be summarized descriptively.  
10.2. Randomization 
This is a prospective, randomized, open -label study, with blinded assessment of efficacy and 
safety (TEs and deaths) o utcomes by the independent EAC.  Patients will be randomized 1:1 to 
andexanet or usual care, stratified by the Investigator’s intended -usual- care-agent, determined on 
a patient -by-patient basis, as well as time from symptom onset to baseline imaging scan.  
10.3. Determination of Sample Size  
Hemostatic efficacy was reported by Sarode et al [7] as 58.3% (95% CI 27.7, 84.8) and 
41.7% (95% CI 15.2, 72.3) for a small sample of ICrH patients receiving FFP and 4F- PCC, 
respectively.  For the overall population, the reported hemostatic efficacy was 65.4% (95% CI 55.4, 74.4) and 72.4% (95% CI 62.5, 81.0) for patients receiving FFP and 4F- PCC, respectively.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 66 Also, in a study evaluating the efficacy of idarucizumab to reverse the effect of dabigatran 
 [11, 26] , the proportion of the overall patient population with an Investigator- assessed time to 
hemostasis less than 24 hours can be estimated to be approximately 66% (95% CI 59, 73).  In addition, in 2 studies evaluating the efficacy of 4F- PCC in patients with FXa inhibitor -related 
major bleeding, hemostatic efficacy was reported as 69.1% (95% CI 58, 79) [ 27] and 
84.8% (95% CI 74, 93) [ 28].  Gerner et al [8] investigated a total of 190 patients with 
intracerebral bleeding over a 5-year period treated with dabigatran (n=22), rivaroxaban (n=142), and apixaban (n=26).  For these patients, the rate of hematoma expansion (defined as an increase 
from baseline of 33% or greater on follow up imaging) was observed to be 35% (th erefore, 
65% of patients did not have hematoma expansion).  Finally, in a retrospective observational cohort of ICrH patients receiving PCCs, hemostatic efficacy was noted to be 81.8% in 
433 efficacy evaluable patients [29]. 
For bleeding patients treated with andexanet, the FXa inhibito r reversal agent being evaluated in 
the current study, results from 477 patients enrolled in a Phase 3b/4 single arm, open-label study 
(ANNEXA-4) as of 30 June 2020 showed an effective hemostasis rate of 79% (95% CI of 
74, 84) for 244 efficacy- evaluable pa tients with ICrH.  Overall, for a total of 340 efficacy 
evaluable patients with all types of bleeding, the rate of effective hemostasis was 80% (95% CI of 75, 84). 
The primary objective of this study is to compare the rate of effective hemostasis between andexanet and usual care in intracerebral hemorrhage patients.  The statistical significance of the 
comparison will be evaluated by a two-sided test with the null hypothesis of no difference.  Based on the hemostatic efficacy results discussed above, it is assumed that the rate of effective 
hemostasis in this study will be approximately 70% and 80% for patients treated with usual care 
and andexanet, respectively.  The 10% absolute difference also represents a 33% risk reduction of not achieving effective hem ostasis by andexanet as compared to usual care, such a magnitude 
is considered clinically meaningful.  After accounting for early discontinuation rate and one interim analysis, it is estimated that a total sample size of approximately 900 patients (i.e., 
450 patients per group) will have approximately 90% power to detect a 10% absolute difference 
between andexanet and usual care in the rate of effective hemostasis at a 0.05 two -sided overall 
significance level.  
10.4. Analysis P opula tions 
10.4.1. Safety  Analysi s Popul ation 
The safety analysis popula tion w ill consi st of all randomized patients who received the study 
treatment (andexanet or usual care) and analyzed according to the actual treatment received.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 67 10.4.2. Efficacy Analysi s Population 
Intent -to-Treat Population (ITT):  The ITT Population will include all randomized patients 
according to the randomized treatment. Participants who are randomized without signing the 
consent form throughout the study will not be included in the ITT set. 
Per-Protocol Population (PP):  The PP Population will include all patients in the ITT 
population who did not have important protocol deviations which impact the primary efficacy 
assessment.  
The full definition of the PP set is  provided in the SAP. 
10.4.3. Patient Disposition  
Patient disposition, including total screened, enrolled, randomized, early terminations, and 
withdrawals, will be presented by treatment assignment.  In addition, a listing will be providing 
with the reasons for screen failures and study discontinuations. 
10.4.4. Baseline and Demographic Characteristics  
Baseline and demographic characteristics will be summarized for both the safety and efficacy populations.  Data will be summarized using descriptive statistics of frequencies for categorical 
data and mea ns, medians, standard deviations, minimums, and maximums for continuous data.  
No inferential analyses of these data are planned.  
10.4.5. Treatment Compliance  
Patient compliance with the assigned treatment will not be evaluated since all procedures are 
performed i n the hospital by a trained professional (for andexanet, any dose modifications will 
also be recorded and presented).  However, lack of compliance or deviation from the study required evaluations will be listed. 
10.5. Efficacy Endpoints and Analyses  
10.5.1. Population 
The primary, secondary, and additional efficacy endpoints will be analyzed using the ITT 
population. 
10.5.2. Definitions  
Hemostatic efficacy will be determined by the blinded EAC.  Cases will be primarily determined 
to have effective hemostasis (i.e., a rating of “good” or “excellent”) or not (i.e., a rating of 
“poor/none”) based on pre-specified criteria documented in the Adjudication Charter and 
summarized in  Appendix B . 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 68 For biomarker endpoint s, the base line measurement w ill be the most recent value drawn within 
120 minutes prior to randomization.  Any baseline measurement collected greater than 
120 minutes prior to randomization will be considered out of window.  
10.5.3. Efficacy Endpoints  
10.5.3.1. Primary Efficacy Endpoint  
The primary efficacy endpoint is based on the achievement of effective hemostasis 12  hours 
post-randomization, as determined by the blinded EAC, based on pre- specified criteria 
documented in the Adjudica tion Charter (see Appendix B ). 
Effective hemostasis will be further defined as:  
• 1 = for patients with hemostatic efficacy rated by the EAC as excell ent or good, and 
• 0 = for patients with hemostatic efficacy rated by the EAC as poor/none. 
For a patient to have excellent or good hemostatic efficacy, he or she must meet all of the 
following criteria:  
• NIHSS score of less than +7 point change from the baseline score at 12 hours 
post-randomization. 
• No greater than 35% increase from baseline in hematoma volume within 12  hours 
post-randomization. 
• Has not received rescue therapy (as defined in Section  7.2, Section  7.3, and 
Section  7.4) between 3 and 12 hours post -randomization 
If data supporting either the imaging or clinical components of the adjudication of hemostatic 
efficacy are missing, ou t-of-window, uninterpretable or confounded (e.g., intubation or sedation), 
cases will be referred for external adjudication by EAC. Procoagulant blood products administered within 3 hours post-randomization to patients randomized to andexanet will be 
reviewed by EAC to determine if they were related to clinical or administrative reasons. 
Surgeries or procedures impacting hematoma volume within 3 hours post- randomization will 
also be reviewed by EAC to determine if related to clinical or administrative reaso ns (see 
Section  7.2, Section  7.3, and Section  7.4). 
Cases where it is determined that there is insufficient information, or when it is not otherwise possible to properly assess the effect of treatment, will be further classified by the EAC as 
‘non-evaluable due to administrative reasons’ (e.g., follow- up scan not available/ performed/ 
interpretable, patient transferred to another facility for administrative purposes) or 
‘non-evaluable due to clinical reasons’ (e.g., patient died, patient had unplanned surgery draining 
hematoma).  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 69 All ITT patients will be included in the primary analysis.  Patients with non -evaluable hemostatic 
efficacy due to clinical reasons will be treated as treatment failures (similar to patients with 
poor/none hemostatic efficacy). Both non- evaluable subjects due to administrative and clinical 
reasons will be included in the denominator for primary efficacy analysis.  
To evaluate the robustness of the primary effic acy results, sensitivity analyses will be performed. 
Further details will be provided in the SAP.  
10.5.3.2. Secondary Efficacy Endpoint 
The secondary efficacy endpoint is: 
• Percent change from baseline to nadir in anti -fXa activity during the first 2 hours 
post-randomization.  
Missing data for anti -fXa activity will be imputed using the multiple imputation method 
described by Rubin (1976) [ 30].  
10.5.3.3. Additional Efficacy Endpoints 
The additional efficacy endpoints include the following: 
• Change from baseline in thrombin  generation parameters (with ETP as the primary 
measure) obtained at 1 and 12 hours post -randomization. 
• Proportion of neurologic deterioration, as defined by NIHSS increase ≥ 4 or a GCS 
score decrease ≥ 2 at 24 hours post-randomization versus baseline. 
• Change from baseline in mRS score at 30 days post-randomization. 
• Change from baseline in NIHSS score obtained at 2, 3, 6, 12, 24, and 72 hours post-randomization.  
• Change from baseline GCS score obtained at 2, 3, 6, 12, 24, and 72 hours post-randomization. 
• Proportion of patients with a ≥ 7- point increase from baseline in NIHSS at 12  hours 
post-randomization. 
• Hemostatic efficacy evaluated using only imaging parameters.  
• Proportion of patie nts receiving rescue therapy between 3 and 12 hours 
post-randomization. 
• Correlation analysis between anti- fXa activity and the achievement of hemostatic 
efficacy.  
• Health -related quality of life as assessed by the EQ -5D questionnaire at 30 days 
post-randomization. 
• UW-mRS score at 30 days post- randomization.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 70 10.5.4.  Statistical Methodology for Efficacy Endpoint Analyses  
10.5.4.1. Control of Family -Wise Error Rate 
A combination of a hierarchical testing procedure and Hochberg Procedure will be used to test 
the primary and the secondary endpoint. 
For the interim analysis, a hierarchical testing procedure will be used to test the primary and the 
secondary endpoint.  The primary endpoint will be tested at an alpha level of 0.031.  If the 
primary endpoint is statistically significa nt, the secondary endpoint will be tested at an alpha 
level of 0.031. 
The final analysis is controlled in a similar fashion, using an alpha level of 0.0277. 
The overall family -wise error rate is controlled at alpha level of 0.05, and accounts for the 
interim and final analyses for the primary and secondary endpoints. 10.5.4.2. Primary Efficacy Endpoint Analysis  
The primary objective of the study is to compare the proportion of patients with effective 
hemostasis (excellent or good as adjudicated by the blinded EAC) between andexanet and usual 
care.  The following hypothesis will be evaluated: 
Ho:  π  UC – π  andexanet  = 0 
HA:  π  UC – π  andexanet  ≠ 0 
Analysis will be performed using a Cochran- Mantel Haenszel (CMH) test stratified by time from 
symptom onset to baseline imaging scan (< 180 minutes vs. ≥ 180 minutes).  The corresponding 95% confidence intervals ( CIs) for the difference in proportions, and the  proportions from the 
two groups, will be provided. 
The study will be considered to meet its primary efficacy objective if the proportion of 
andexanet- treated patients with effective hemostasis (excellent or g ood as adjudicated by the 
independent EAC) is significantly higher (p < 0.031 at the interim analysis, OR p<0.0277 at the final analysis) than the proportion of patients with effective hemostasis randomized to usual care.  
A sensitivity analysis will be performed using a CMH test stratified by intended -usual- care-agent 
and time from symptom onset to baseline imaging scan.  
Further details of the primary analysis will be provided in the SAP.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 71 10.5.4.3. Secondary Efficacy Endpoint Analysis 
Anti -fXa Activity  
The secondary objective of this study is to evaluate the effect of andexanet versus usual care on 
anti-fXa activity.  The change, percent change in anti- fXa activity from baseline (most recent 
measurement prior to randomization) through the 2 -hour time-point, and the mi nimum anti -fXa 
activity post -randomization (i.e., the nadir) will be summarized.   
The secondary endpoint is the percent change in anti- fXa activity from baseline to nadir during 
the first 2 hours post-randomization.  The analysis of this endpoint will be an Analysis of 
Covariance (ANCOVA) on the ranked data, including time from symptom onset to baseline 
imaging scan (<  180 minutes vs. ≥ 180  minutes), and baseline anti -fXa activity as covariates.  
10.5.4.4. Additional Efficacy Analyses  
Thrombin generation parameters (with ETP as the primary measure) will be obtained at baseline, 1 hour, and 12 hours post-randomization.  T he difference between the two treatment groups will 
be evaluated using a mixed effects model similar to the model described below for the analysis of the NIHSS and GCS scores.  
The change from baseline in NIHSS and change from baseline in GCS will be analyzed using a mixed linear model with covariates, including the baseline measurement and the following fixed 
effect terms:  
• Stratification factor of time from symptom onset to baseline imaging scan 
(< 180 minutes vs. ≥ 180 minutes) 
• Treatment arm (usual care/andexanet)  
• Time (measurements at 2, 3, 6, 12, 24, and 72 hours post- randomization)  
• Treatment -by-time interaction  
Patients will be treated as a random effect to take account of the correlation of the measurements 
within the same patient.  
Neurologic deterioration at 24 hours defines deterioration as meeting at least one of the 
following 2 criteria:  
• An increase in NIHSS score ≥ 4 at 24 hours post- randomization compared with 
baseline;  
• A decrease in GCS score ≥ 2 at 24 hours post- randomization compared with baseline.  
The CMH test stratified by time from symptom onset to baseline imaging scan will be used to 
test the treatment difference in the proportion of neurologic deterioration at 24 hours. 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 72 Change from baseline in mRS scores at 30 days post-randomization will be analyzed using a 
proportional odds model adjusted for baseline mRS, the stratification factor, treatment arm, and 
potentially other clinica l factors.  
The relationship between anti- fXa activity and the achievement of clinical events such as 
hemostatic efficacy and mortality will be evaluated.  A logistic regression adjusted for 
potentially other clinical factors, the stratification factor in the primary efficacy analysis, and 
treatment arm will be used to evaluate the relationship.  
Further details of these analyses will be provided in the SAP. 
10.6. Safety Endpoints and Summaries  
The following safety endpoints will be evaluated: 
• Occurrence of TEs, confirmed by adjudication, through 30 days post- randomization.  
• In-hospital mortality (during index hospitalization; all- cause, cardiovascular [CV], 
and bleeding).  
• 30-day all-cause, CV, and bleeding mortality (the latter defined as death within 
72 hours of randomization, not due to a TE). 
• Proportion of patients with invasive intracranial procedures performed post- randomization to manage the intracranial hematoma and/or its complications.  
• Length of initial hospitalization for primary bleeding event.  
• Total time admitted to the intensive care unit during the initial hospitalization.  
• Proportion of re -hospitalizations, including total number of re-hospitalizations and 
total days re-hospitalized, at 30 days post-randomization. 
• AEs and vital signs. 
• Antibodies t o FX, FXa, and andexanet. 
• Neutralizing antibodies to FX, FXa, and andexanet. 
Safety will be assessed by exa mination of AEs (including central adjudication of TEs), survival 
status (including central adjudication of deaths), occurrence of invasive procedures, 
hospitalization data, laboratory parameters (i.e.,  antibody testing), and vit al signs.  Only 
clinically significant changes will be reported as AEs (see Section  8.1). 
10.6.1. Adverse Events  
Treatment -emergent adverse events (TEAEs) w ill be summari zed by sy stem o rgan cl ass and 
preferred terms as defined by the Medical Dictionary for Regulatory Activities (MedDRA) with 
the version in effect at the time of analysis.   
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 73 The num ber of  even ts, the num ber of patients, a nd the perc entage of patients who ex perienced  at 
least one TEAE w ill be p resen ted.  TE AEs that are considered by the Inv estigator to be related t o 
a study- related procedure; TE AEs that lead to ear ly withd rawals; and s erious TEA Es will be 
summari zed in the sam e manner.  Frequent TEAEs, includi ng pref erred terms with an incidence 
rate of ≥ 5%,  will also be summari zed. 
Concomitant medications will be coded us ing the World Health Organization ( WHO) Dr ug 
Dictionary (DD).  
10.6.2. Thrombotic Events  
All potential TEs up to the Day 30 visit will be assessed by the EAC and summarized 
descriptively.  The Investigator will determine whether a TE is attributable to andexanet, while 
the DSMB will determine whether the occurrence of TEs in aggregate (related  or not) warrant 
changes to the study.  In addition to Investigator reporting, ongoing periodic review of AEs to identify potential TEs to be submitted for adjudication will be conducted by the Sponsor.  
Detailed definitions of TEs assessed by EAC (includi ng arterial systemic embolism, DVT, MI, 
PE, stroke, and TIA) will be provided in the Adjudication Charter as well as in Appendix K . 
10.6.3. Deaths  
All death s will be assessed by the blinded EAC. Deaths will be summarized by all cause, death 
adjudicated as due to CV or non-CV causes, and death due to bleeding. In hospital deaths and 30-day mortality by all cause will be also summarized . 
Thirty -day mortality wi ll be analyzed using a Cox proportional hazards model (for survival), 
with analyses adjusted for the stratification factor as in the primary efficacy analysis treatment 
arm, and potentially other clinical factors.  Details will be provided in the SAP.  
10.6.4. Inva sive Procedures  
The number of patients with invasive intracranial procedures performed post-randomization will 
be summarized descriptively.  All surgeries and interventional procedures specifically intended 
to manage the hematoma and/or its complications w ill be counted, including Burr holes, 
craniotomies, and placement of intraventricular catheters.  
10.6.5. Hospitalizations  
The length of initial hospitalization for primary bleeding event, the total time spent in the 
intensive care unit in the initial hospitalization, and the occurrence of re- hospitalizations 
(including total number of re -hospitalizations and total days re-hospitalized) up to 30 days post-
randomization will be summarized descriptively.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 74 10.6.6. Laboratory Para meters 
The results of antibody assay s including those for FX, FXa, and andexanet, and results for other 
safety laboratory parameters,  will be summarized by time-point.  Neutralizing antibodies for the 
above epitopes will be summarized by time -point as appropriate. 
10.6.7. Vital Signs  
Vital sig ns will be su mmarized us ing actual values and chang e from baseli ne at pre -specified 
time-points for e ach trea tment group.  Descrip tive statistics, including threshold-b ased outli er 
analy ses, will  be presented.  
10.7. Interim Analyses  
One planned, formal interim analysis on the primary efficacy endpoint will be performed by the 
DSMB- associated statistician after 50% of the anticipated participants has been adjudicated for 
hemostatic efficacy. DSMB will evaluate the results and recommend  altering or stopping the 
study in the event of prespecified  efficacy. Enrollment will not be paused during the interim 
analysis.  
10.7.1. Stopping Criterion Due to Efficacy at Interim  
The overall type I error for the interim and final analysis is controlled at 5% by employing the 
alpha spending function by Lan and DeMets based on Pocock boundaries [ 6]. If the interim 
p-value < 0.0310 for comparing andexanet and usual care in the primary endpoint analysis, 
DSMB may recommend stopping the study. In this case, the efficacy results from the interim 
analysis (with 50% of the anticipated participants) will be used for regulatory communication 
and submission.  Enrollment of patients will proceed without interruption while the analysis is 
ongoing, resulting in more than 50% of the anticipated participant in the final data cutoff; 
efficacy analysis on the final data cutoff will be considered as supportive.  
10.7.2. Sample Size Re -estimation at Interim  
If the DSMB re commendation at interim is to continue the study, a pre- planned sample size 
re-estimation (SSR) will be performed by the DSMB -associated statistician with the interim data. 
The SSR will be based on a conditional power (CP) of comparing andexanet and usual care at 
final (n=900) given the interim data, using a promising zone between 30% and 90% [31]. The 
assumption used for CP calculation is that the rate of hemostatic efficacy in andexanet and usual care at final is 80% and 70%, respectively. Based on the observed CP, DSMB will recommend:  
• No increase in sample size, if the CP < 30% or  > 90%;  
• Increase the sample size to up to 1200 if 30% ≤ CP ≤ 90%. 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 75 10.7.3. Primary Analysis if Study is Continued from Interim  
When no change in sample size occurs (i.e., interim decision to keep the original planned sample 
size), the conventional Cochran–Mantel –Haenszel (CMH) statistics will be used at final to 
determine statistical significance [1].   
In contrast, if the total sample size is increased per interim analysis decision, then the final 
analysis will use the weighted statistic proposed by Cui, Hung, and Wang (2004) [ 32].  
In this case, the test statistic at final is a weighted sum of the test statistic at interi m (stage 1, 
n1 = 450), and the test statistics based on additional participants (stage 2, n2 =750); the weight is 
0.5 to avoid introducing bias . The weighted statistics is calculated as below  
𝑍𝑍CHW =√𝑤𝑤 𝑍𝑍1+√1−𝑤𝑤  𝑍𝑍2 
and w =  0.5, Z 1 and Z 2 are the CMH test statistics at stage 1 and stage 2, respectively.  
10.8. Subgroup Analyses  
Subgroup analyses may include, but not necessary be limited to, the following parameters:  
baseline anti -fXa activity above and below 30 ng/mL, baseline anti- fXa activity above and below 
75 ng/mL, age (less than 65, 65-74, 75 or greater), sex, race (all groups with 5 or more patients), geographical region (North America, Europe, Asia), FXa inhibitor at randomization, indication 
for FXa inhibitor (atrial fibrillation, VTE, other), time at randomization since last FXa inhibitor 
dose (within 8 hours or more than 8 hours), andexanet dose, hematoma expansion risk as 
measured by baseline hematoma volume ( < 30 mL, ≥ 30 mL ; < 0.5 mL, ≥  0.5 mL), 
determination of ICrH score at baselin e(< 3, ≥ 3) , baseline intracranial bleed location, and usual 
care received (andexanet vs PCC, andexanet vs non- PCC). 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 76 11.0  STUDY COMMITTEES AND COMMUNICATIONS  
Charters have been established accordingly for the committees.  In brief, the purpose of each 
committe e is as follows:  
• Independent EAC:   The EAC will oversee the adjudication of hemostatic efficacy 
within the first 12 hours post-randomization.  Additionally, all TEs and deaths will be 
adjudicated.  The EAC will remain blinded to treatment assignment for all patients.  
• Independent DSMB:   Monitor all safety and efficacy data.  Evaluate interim analysis 
performed by the independent statistician and make recommendations for study 
modification or stopping due to efficacy or safety reasons. 
• Steering Committee:  Ov erall governance and oversight of the study; assessment 
and management of country- specific or region -specific issues and activities.  
• Executive Committee:   Oversight of general study conduct and ad hoc issues as they 
arise  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 77 12.0 INVESTIGA TOR AND ADM INISTRAT IVE REQUIREMENTS 
12.1. Institutional Review Board or I ndepe ndent E thics Committee 
This study will be conducted in accordance with the protocol and the following:  
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and CIOMS International Ethical Guidelines.  
• Applicable ICH GCP Guidelines.  
• Applicable laws and regulations.  
The protocol, substantial protocol amendments, ICF, IB, and other relevant documents (e.g., 
advertisements) must be submitted to an IRB/IEC by the Investigator/Sponsor and reviewed and 
approved by the IRB/IEC before the study is initiated.  If any of these documents require 
regulatory/he alth authority approval per local regulations, the Sponsor will also obtain such 
approval before the study is initiated.  Any substantial amendments to the protocol will require IRB/IEC and, per local regulations, regulatory/health authority approval befor e implementation 
of changes made to the study design except for changes necessary to eliminate an immediate hazard to study participants.  The Investigator will notify the IRB/IEC of deviations from the 
study protocol or GCP as defined by UK legislation as a serious breach or as required by 
IRB/IEC procedures.  
The Investigator will be responsible for the following: 
• Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC.  
• Notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC procedures.  
• Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, Directive 2001/20/EC, EU Clinical Trial Regulation (No. 536/2014) (if applicable), and all other applicable local regulations. 
After the c ompl etion or t ermination of  the study, the Inve stigator w ill submit a report to the  IRB 
or IEC and to the Sponsor . 
12.2. Informed  Conse nt 
It is the responsibility of the Investigator or designee to obtain signed (written or electronic 
signature) informed consent (and assent, where applicable) from all study participants or the 
participant’s LAR prior to pe rforming any study-related procedures, including screening 
assessments.  
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 78 The Investigator or designee will explain the nature of the study (including but not limited to the 
objectives, potential benefits and risks, inconveniences, and the participant’s rights and 
responsibilities) to the participant or his/her LAR, defined according to local and country 
regulations where the study is taking place, and answer all questions regarding the study. 
Participants must be informed that their participation is voluntary.  Participants or their LAR will 
be required to sign a statement of informed consent (or assent) or a certified translation, if 
applicable, that meets the requirements of 21 CFR 50, local regulations, EU General Data 
Protection Regulation (GDPR), ICH GCP  guidelines, Health Insurance Portability and 
Accountability Act (HIPAA) requirements, where applicable, and the IRB/IEC or study center.  
The participant’s medical record must include a statement that signed (written or electronic) 
informed consent (or ass ent) was obtained before any screening procedures were performed with 
a participant, and the date the written consent was obtained.  The authorized person obtaining the informed consent (or assent) must also sign the informed consent (or assent) form(s).  
Participants or their LAR must be re -consented (or re- assented) to the most current version of the 
informed consent (or assent) form(s) during their participation in the study, as applicable.  
A copy of the signed (written or electronic) informed consent (or assent) documentation (i.e., a complete set of participant information sheets and fully executed signature pages) must be 
provided to the participant or the participant’s LAR, as applicable. This document may require 
translation into the local language. O riginal signed (written or electronic) consent (or assent) 
forms must remain in each participant’s study file and must be available for verification at any time.  
Because of the critical nature of the illness under study and the possibility that patients wi ll be 
unable to provide their own consent, proxy consents (defined as consent from an LAR) and/or 
emergency consents (defined as consent from a qualified medical professional) are allowed if permissible by local or regional laws and regulations. 
12.3. Supplementary Docu mentation 
Before initiation of t he study, the In vestigator must prov ide the Sponsor  with the fo llowing 
docum ents (cop ies of wh ich m ust be maintained by the Investigator ): 
1. Curricul um vitae of the Inves tigator and any sub-Inves tigator s listed on t he Form 
FDA 1572. 
2. A signed copy of the IRB or I EC approval noti ce for protocol and infor med consent. 
3. A copy of t he IRB- or IEC-approved ICF. 
4. Labo ratory certification w ith a list of  norma l values for laboratory te sts th at will be 
conducted a t local labor atories. 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 79 5. Completed financia l disclosure for m for the Investigator and any sub-inves tigator s listed 
on the Form FDA 1572.  Investigators and sub- investigators will provide sufficient and 
accurate financial information as requested to allow the Sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate regulatory 
authorities.  Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after study completion. 
12.4. Data Collection and Management Responsibilities  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the site Investigator.  The Investigator is responsible for ensuring the accura cy, completeness, 
legibility, and timeliness of the data reported.  
All source documents should be completed in a neat, legible manner to ensure accurate 
interpretation of data.  Data recorded in the eCRF derived from source documents should be 
consistent w ith the data recorded on the source documents. 
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical laboratory data will be entered into a 21 CFR Part 11 -compliant Electronic Data Capture 
(EDC) system, as  appropriate.  The data system includes password protection and internal 
quality checks, such as automatic range checks, to identify data that appear inconsistent, 
incomplete, or inaccurate.  Clinical data will be entered directly from the source documents .  
Some clinical laboratory data will be collected externally from the EDC systems.  Further details for data collection and data handling will be specified in the data management plan, CRFs, 
instructions for completing forms, other data handling procedures, and procedures for data 
monitoring.  MedDRA coding dictionary will be used for coding AEs, medical history 
conditions, and procedure.  The reconciliation of the SAEs between the clinical and safety databases will be conducted as specified in plans deter mined and approved prior to study 
start-up.  The WHO-DD will be used to code medications. 
12.5. Study Records Retention  
Study documents should be retained for a minimum of 2 years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2  years have elapsed since the formal 
discontinuation of clinical development of the study intervention.  These documents should be retained for a longer period, however, if required by local regulations.  No records will be 
destroyed without the written consent of the Sponsor, if applicable.  It is the responsibility of the 
Sponsor to inform the Investigator when these documents no longer need to be retained. 
12.6. Deviation from the Protocol 
The Investigator w ill not deviate from the protocol.  In medi cal emergencies, t he Inves tigator 
will use me dical ju dgment and w ill remove the patient  from immedia te hazard, and then noti fy 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 80 the Sponsor’s Medi cal Monitor  and the IRB or I EC immediately reg arding the type of 
emergency and cour se of action take n.  Any action in thi s regard w ill be r ecorded on the 
appropriate CRF.  Deviations due to non- compliance that render patient non -evaluable for key 
endpoints will be considered important deviations.  Any other changes or devia tions in the 
protocol w ill be made a s an amendment to the protocol and must be approved by the Sponsor  
and the IRB or I EC b efore the changes or devia tions are implemented.  The Sponsor  will not 
assume any responsibility or liability for any de viation or chang e that is not described as part of 
an amendment to the protocol . 
12.7. Disclosure of Data  
Individua l patient me dical informa tion obtained a s a result of this study is considere d 
confiden tial and disclosure to third p arties other than those noted bel ow is prohib ited.  Patient  
confidentiality w ill be fur ther assured by utiliz ing patient id entifi cation code number s to 
corre spond to tr eatment data in the computer f iles.  The study p ersonnel, employees of the 
regulatory agencies, including the US FD A and the study Sponsor and it s agent s will need to 
review patient medical records in order to accurately r ecord informa tion for t his stud y.  If results 
of this stu dy are reporte d in m edica l journals or a t meetings, the patient ’s identity w ill remain 
confi
dential. 
12.8. Drug  Accountability  
The Investigator must maintain accurate records of the amounts and dates andexanet was 
received from the Sponsor and prepared for the study, including the volume and concentration of 
stock solution prepared and remaining stock solution volume after dose preparation.  All drug 
supplies must be accounted for at the termination of the study and a written explanation provided 
for any discrepancies.  All partially used or unused drug supplies will be destroyed at the site, in 
accordance with approved written procedures, or returned to the Sponsor after written authorization is obtained from the Sponsor’s Clinical Development department.  The Investigator 
will maintain a record of the amount and dates when unused supplies were either destroyed or 
returned to the Sponsor.  All records will be retained as noted in Section 12.5. 
12.9. Study Monitoring 
Study monitors will perform ongoing source data verification to confirm that data entered into 
the eCRF by authorized site personnel ar e accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, an d all applicable regulatory requirements.  Remote source data 
verification may be employed where permitted by local regulations.  The scope of the source data verification is described in detail in the Clinical Monitoring Plan.  
The Inve stigator /institution w ill permit trial -related monitoring, audits, IRB/IEC review, and 
regulatory inspection(s), providing direct access to source data/documents.  The IRB/IEC and 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 81 representa tives of the Sponsor  will be allowed to per iodically audi t (at mutually convenient 
times before, during, and after the study ha s been complete d) all CRF s and relevant po rtions of 
office, clinical, and laboratory recor ds for each patient.  Appropriat e sou rce document s, 
including document s that sup port patient eligib ility (e.g., med ical history, concomit ant 
medi cations) should be made ava ilable to the study mon itor and to the IRB/IEC .  The monito ring 
visits p rovide the Sponsor and the IRB/IEC  with the opportunity to evaluate the pr ogress of the 
study ; verify the a ccuracy and completene ss of CRF s; assure tha t all protocol requi rements, 
app
licabl e regula tions, and Investigator's obliga tions are bei ng fulfilled; and resolve any 
inconsistencie s in the study r ecords. 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 82 13.0 REFERE NCES 
1. Held, C., et al., Clinical outcomes and management associated with major bleeding in 
patients with atrial fibrillation treated with apixaban or warfarin: insights from the 
ARISTOTLE trial.  Eur Heart J, 2015. 36(20): p. 1264-72. 
2. Hankey, G.J., et.al., Intracranial Hemorrhage Among Patients With Atrial Fibrillation 
Anticoagulated With Warfarin or Rivaroxaban The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation.  stroke, 2012: p. 1304-1312. 
3. Giugliano, R.P., et.al., Cerebrovascular Events in 21 105 Patients With Atrial 
Fibrillation Randomized to Edoxaban Versus Warfarin Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation -Thrombolysis in Myocardial Infarction 
48. Stroke, 2014. 45: p. 2372-2378. 
4. Asch, C.J.J., et.al., Incidence, case fatality, and functional outcome of intracerebral 
haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. The Lancet, 2010. 9: p. 167-176. 
5. Davis, S.M.e.a., Hematoma growth is a determinant of mortality and poor outcome after 
intracerebral hemorrhage.  Neurology, 2006. 66(8): p. 1175-1181. 
6. Dowlatshahi, D., et.al., Defining hematoma expansion in intracerebral hemorrhage. 
Neurology, 2011. 76: p. 1238-1244. 
7. Sarode, R., et al., Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in 
Patients on Vitamin K Antagonists Presenting With Major Bleeding: A Randomized, Plasma -Controlled, Phase IIIb Study. Circulation, 2013. 128: p. 1234-1243. 
8. Gerner, S.T., et.al., Association of Prothrombin Complex Concentrate Administration and 
Hematoma Enlargement in Non–Vitamin K Antagonist Oral Anticoagulant–Related Intracerebral Hemorrhage.  Annals of Neurology, 2018. 83(1): p. 186-196. 
9. Khorsand, N., et.al., Assessment of effectiveness of major bleeding management: 
proposed definitions for effective hemostasis: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016(14): p. 211-214. 
10. Bayer -Westendorf, J., Rates, management and outcomes of bleeding complications 
during rivaroxaban therapy in daily care – results from the Dresden NOAC registry.  
Blood, 2014. 124: p. 955-962. 
11. Pollack, C.V.J., et al., Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. 
NEJM, 2017. 377: p. 431-441. 
12. Hemphill, J.C., 3rd, et al., Guidelines for the Management of Spontaneous Intracerebral 
Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2015. 46(7): p. 2032-60. 
13. Brott, T., et.al., Early Hemorrhage Growth in Patients With Intracerebral Hemorrhage.  
Stroke, 1997. 28: p. 1-5. 
14. Purrucker, J.C., Haas, K., Rizos, T., et.al., Early clinical and radiological course, 
management, and outcome of intracerebral haemorrhage related to new oral anticoagulants. JAMA Neurology, 2016(73): p. 169-177. 
15. Leil, T.A., Feng Y., Zhang L., Paccaly A., Mohan P., Pfister M. , Quantification of 
Apixaban’s Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose.  Clin Pharm & Therap, 2010. 88(3): p. 375-382. 
16. Agnelli G, G.A., Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz 
F, Schellong S; ODIXa -DVT Study Investigators. , Treatment of proximal deep- vein 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 83 thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the 
ODIXa -DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute 
Symptomatic Deep-Vein Thrombosis) study.  Circulation, 2007. 116(2): p. 180-7. 
17. Mueck, W., Becka M., Kubitza D., Voith B., Zuehlsdorf M. , Population Model of the 
Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Healthy Subjects. Intern ational J of Clinic Pharm and Therap, 2007. 45(6): 
p. 335-344. 
18. Wong, P.C., Pinto D.J.P., Zhang D. , Preclinical Discovery of Apixaban, a Direct and 
Orally Bioavailable Factor Xa Inhibitor.  J Thromb Thrombolysis, 2011. 31: p. 478-492. 
19. Kubitza, D., et al., Safety, pharmacodynamics, and pharmacokinetics of single doses of 
BAY 59 -7939, an oral, direct factor Xa inhibitor.  Clin Pharmacol Ther, 2005. 78: p. 412-
21. 
20. Mueck, W., Schwers S., Stampfuss J. , Rivaroxaban and other novel oral 
anticoagulants:pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring.  Thrombosis Journal, 2013. 11(1): p. 10. 
21. Orfeo, T., Butenas S, Brummel- Ziedins KE, Gissel M, Mann KG, Anticoagulation by 
factor Xa inhibitors.  Journal of Thrombosis and Haemostasis, 2010. 8(8): p. 1745-1753. 
22. Hollenbach, S., Lu, G., Tan, S., Lee, G., Hutchaleelaha, A., et al., PRT064445 but not 
rfVIIa or PCC Reverses Rivaroxaban Induced Anticoagulation as Measured by Reduction in Blood Loss in a Rabbit Liver Laceration Model . 2012, ASH: Portola 
Pharmaceuticals, Inc. South San Francisco, CA.  
23. Patel, M., et.al., Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation.  Journal of the American College of 
Cardiology, 2015. 61(6): p. 651-658. 
24. Granger, C.B., et.al., Clinical events after transitioning from apixaban versus warfarin to 
warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in At rial Fibrillation (ARISTOTLE) trial.  American Heart Journal, 2015. 169 (1): 
p. 25-30. 
25. Cavallari, I., et.al., Clinical events after interruption of anticoagulation in patients with 
atrial fibrillation: An analysis from the ENGAGE AF -TIMI 48 trial.  Intern ational Journal 
of Cardiology, 2018(257): p. 102-107. 
26. Pollack, C.V.J., Reilly, Paul A., Eikelboom, John., et. al., Idarucizumab for Dabigatran 
Reversal.  New England Journal of Medicine, 2017. 373(6): p. 511-520. 
27. Majeed, A., et.al., Management of rivaroxaban- or apixaban- associated major bleeding 
with prothrombin complex concentrates: a cohort study. Blood, 2017. 130(15): p. 1706-1712. 
28. Schulman, S., et al., Prothrombin Complex Concentrate for Major Bleeding on Factor Xa 
Inhibitors: A Prospective Cohort Study. Thromb Haemost, 2018. 118(5): p. 842-851. 
29. Panos, N.G., et al., Factor Xa Inhibitor-Related Intracranial Hemorrhage (FiX- ICH): 
Results from a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates. Circulation, 2020. 
30. Rubin, D.B., Inference and missing data. Biometrika, 1976. 63 (3): p. 581-92. 
31. Mehta, C. and S. Pocock, Adaptive increase in sample size when interim results are 
promising: a practical guide with examples. Stat Medicine, 2011. 30: p. 3267-3284. 
32. Cui, L., H.M. Hung, and S.J. Wang, Modification of sample size in group sequential 
clinical trials.  Biometrics, 1999. 55(3): p. 853-7. 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 84 33. Levi, M., et al., Guidelines for the diagnosis and management of disseminated 
intravascular coagulation. British Committee for Standards in Haematology. British J 
Haematology, 2009. 145: p. 24-33. 
34. van Diepen, S., et.al., Contemporary Management of Cardiogenic Shock: A Scientific 
Statement From the American Heart Association.  Circulation, 2017. 136(16): p. e232-
e268. 
35. Dellinger RP, et al., Surviving sepsis campaign: International guidelines for management 
of severe sepsis and septic shock: 2012.  Critical Care Medicine, 2013. 41(2): p. 580-637. 
 
Protocol Amendment 3   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 85 14.0 LIST OF APPENDICES  
Appendix A : Schedule of Activities  
Appendix B : Adjudication Criteria for Hemostatic Efficacy  
Appendix C : Glasgow Coma Scale (GCS)  
Appendix D : Modified Rankin Scale (mRS) 
Appendix E : National Institute of Health Stroke Scale (NIHSS) 
Appendix F  : Covid-19:  Potential Risks and Mitigation Measures 
Appendix G : Examples of Planned Minimally Invasive Surgeries/Procedures Allowed   
Appendix H : Disseminated Intravascular Coagulation Scoring Algorithm  
Appendix I : Definitions of Severe Sepsis and Septic Shock  
Appendix J : Definition of Female of Childbearing Potential  
Appendix K : Guidance for Submission of Potential Thrombotic Events for 
Adjudication 
Appendix L : EuroQol- 5 Dimension (EQ -5D) Questionnaire  
Protocol Amendment 3  ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022 Page 86 APPENDIX A.  SCHEDULE OF ACTIVITIES  
 Screening & 
Baseline Randomization  Treatment Follo w-Up 
STUDY DAY:  1 2 3 7 16 14 16 30 17 
or ET  
TIME -POINT AND 
WINDOW:  
All time -points relative to 
randomization -2 
hours 
to -1 
min -15 min 
to -1 min  0 Within 
30 min  
 1 hour  
± 15 
min 2 hours  
± 15 
min 3 hours  
± 15 min  6 hours  
± 30 min  12 hours  
± 1 hour  24 
hours  
± 
2 hours  48 
hours  
± 
3 hours  72 
hours  
± 4 
hours  + 3 
days + 6 
days + 7 
days 
Obtain Consent 1 X               
Determine Eligibility  X               
Obtain Medical History 2 X               
Obtain Prior Medications 2 X               
Vital Signs (SBP, DBP, HR, 
RR, temp)  X    X X  X X X X X   X 18 
Height and weight 3 X               
Central Lab: Anti -fXa 
Activity4   X   X X          
Central Lab:  Thrombin 
generation X    X    X       
Central Lab:  Antibodies to 
FX, FXa, andexanet;  
neutralizing antibodies to FX, 
FXa, andexanet  X              X 19 
Central Lab:  TFPI Activity22  X   X X   X      X 
Local Lab:  Pregnancy Test 5 X               
Local Labs: Haematology, 
Coagulation, and Serum 
Chemistry (performed per local 
practice)  X        X      X 18 
Protocol Amendment 3  ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022 Page 87  Screening & 
Baseline Randomization  Treatment Follo w-Up 
STUDY DAY:  1 2 3 7 16 14 16 30 17 
or ET  
TIME -POINT AND 
WINDOW:  
All time -points relative to 
randomization -2 
hours 
to -1 
min -15 min 
to -1 min  0 Within 
30 min  
 1 hour  
± 15 
min 2 hours  
± 15 
min 3 hours  
± 15 min  6 hours  
± 30 min  12 hours  
± 1 hour  24 
hours  
± 
2 hours  48 
hours  
± 
3 hours  72 
hours  
± 4 
hours  + 3 
days + 6 
days + 7 
days 
Head CT or MRI 6 
X      
 
  
   X  
(11-15 hrs 
allowable)        
NIH Stroke Scale Score  X     X X X X14 X14  X    
Glasgow Coma Scale Score  X     X X X X14 X14  X    
Modified Rankin Scale Score  X 15              X 
EQ-5D               X 
Randomization   X             
Andexanet arm:   
Administer  andexanet bolus 
immediately followed by 
an infusion 7   
 Bolus + Infusion  
Initiate no later than 
30 min after 
randomization, and 
preferably within 2 hours 
of the baseline brain 
imaging scan.20         
 
Usual Care arm:   
Administer usual  care 8    X       
Record Blood Products & 
Hemostatic Treatments 9   
 X X X X X X X 
Record Intracerebral 
hemorrhage- related Diagnostic 
& Therapeutic Procedures 10   
 X X X X X X X 
Protocol Amendment 3  ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022 Page 88  Screening & 
Baseline Randomization  Treatment Follo w-Up 
STUDY DAY:  1 2 3 7 16 14 16 30 17 
or ET  
TIME -POINT AND 
WINDOW:  
All time -points relative to 
randomization -2 
hours 
to -1 
min -15 min 
to -1 min  0 Within 
30 min  
 1 hour  
± 15 
min 2 hours  
± 15 
min 3 hours  
± 15 min  6 hours  
± 30 min  12 hours  
± 1 hour  24 
hours  
± 
2 hours  48 
hours  
± 
3 hours  72 
hours  
± 4 
hours  + 3 
days + 6 
days + 7 
days 
Record Hours in ED, 
ICU/Critical Care, General 
Hospital Floor, and total as an 
Inpatient and document 
Rehospitalization 11   
 X X X X X X X 
Record Adverse Events 21 X   X X X X X X X 
Record Concomitant 
Medications 12   
 X X X X X X X 
Ascertain Survival Status     X X X X X X X 
Blood Pressure Management13 X X X X X X X    
BP = blood pressure; CBC = complete blood count; CRF = case report form; CT = computed tomography; DBP = diastolic blood pressure; ED  = emergency 
department; EQ -5D = EuroQol-5 Dimension; ET  = Early Termination; FX  = Factor  X; FXa  = Activated factor X; GCS  = Glasgow Coma Scale; HR  = heart 
rate; hrs  = hours; ICU  = intensive care unit; INR = international normalized ratio; IV  = Intravenous; lab  = laboratory; min  = minute(s); MRI = magnetic 
resonance imaging; mRS  = Modified Rankin Scale; NIH  = National Institutes of Health; NIHSS  = National Institutes of Health Stroke Scale; RR = respiratory 
rate; SAE  = serious adverse event; SBP  = systolic blood pressure; TE  = thrombotic event; temp  = temperature 
1 Unless exception for informed consent for emergency procedures has been obtained and only in accordance with local laws and regulations.  
2 Obtain as much of a full medical history and list of concomitant medications as feasible prior to initiation of study -specific procedures.  
3 If no t possible to measure height or weight, a reported height or weight, or a recent measurement  from the medical record is acceptable.  
4 Samples for anti -fXa activity should be drawn at three time -points; one at baseline and at 1 - and 2 -hours post -randomization.  
5 Pregnancy test in females of childbearing potential only; test may be done on urine or serum.  
6 Data from the head CT or MRI done to confirm the diagnosis or establish the extent of intracerebral hemorrhage will be recorded as the baseline time- point  and 
must occur within 2 hours prior to randomization.  A repeat baseline CT or MRI prior to randomization is permitted.  
7 For patients randomized to andexanet, andexanet will be given via an IV bolus administered over ~15 to 30 minutes followed immediately by a continuous 
infusion administered over ~120 minutes.   
8 For patients randomized to usual care, Investigators may in itiate, within 3 hours of randomization any available therapy (including no treatment) other than 
andexanet to control bleeding and manage their patient during the 12- hour post -randomization period.  Treatment duration will depend on usual care used.  
9 Record blood products and hemostatic treatments used specifically for treatment of intracerebral hemorrhage.   
10 Record procedures performed to evaluate bleeding source/extent and for treatment of intracerebral hemorrhage.  This should include CT or MRI scans.  
Protocol Amendment 3  ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022 Page 89 11 Record through initial hospital discharge and rehospitalization (as applicable).  
12 Record dates of use of anticoagulant(s) on the anticoagulant CRF.  
13 To minimize the effects of blood pressure on hematoma expansion, Investigators should consider maintaining SBP at a target of  140 mmHg as medically 
warranted in both treatment arms.  
14 The 12 -hour and 24- hour NIHSS and GCS assessments must be performed in a blinded manner.  
15 The mRS should reflect the patient’s neurological status prior to acute illness (pre -morbid).  
16 The Day 7 and Day 14 visits may be conducted by phone.  
17 Window:  Days 30 -37.  Patients who discontinue from the study before this visit should undergo an Early Termination visit.  
18 To be performed at Early Termination only if these assessments have not yet been performed at any point during treatment.  
19 Patients with a positive anti -andexa net antibody response at the Day 30 visit should return for a follow up anti -andexanet antibody test within 30 days of when 
the positive test is communicated to the Investigator, or approximately 120 days post -randomization, whichever is later.  Only patients with a positive Day 30 
anti-andexanet antibody test result are required to return for this visit.  Adverse events, concomitant medications and survival s tatus will also be collected.  
20 To accommodate dosing within 2  hours of the baseline scan closest to randomization, reconstitution of andexanet prior to randomization will be allowed.  
21 Adverse events including SAEs and TEs, and survival will be followed through the Day 30 post- treatment visit for all patients.  
22 TFPI activity measurements will be included for plasma samples collected for anti -fXa activity (baseline [ -15min to -1min], 1h, and 2h), thrombin generation 
(12h) and neutralizing antibodies FX/FX a (30d).
Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022 Page 90 APPENDIX B.  ADJUDICATION CRITERIA FOR HEMOSTATIC EFFICACY  
Excellent  
(effective)  • Change from baseline in NIHSS of +6 or less at the 12 -hour time -point, AND the 
following imaging criteria:  
• ≤ 20% increase in hematoma volume compared to baseline on a repeat CT or  MRI 
scan performed at the 12 -hour time -point.  
• No rescue therapiesa administered between 3 hours and 12 hours after randomization.  
Good  
(effective)  • Change from baseline in NIHSS of +6 or less at the 12 -hour time -point, AND the 
following imaging criteria: 
• > 20% but ≤  35% increase in hematoma volume compared to baseline on a repeat CT 
or MRI scan at any time between the completion of initial randomized treatment and 
the 12- hour time -point.  
• No rescue therapiesa administered between 3 hours and 12 hours after randomization.  
Poor/None   
(not effective)  • If a patient meets any one of the following criteria, they are considered to have poor/none hemostatic efficacy:  
• Change from baseline in NIHSS of +7 or more at the 12- hour time -point.  
• >35% increase in h ematoma volume compared to baseline on a repeat CT or MRI 
scan performed at any time between the completion of initial randomized treatment and the 12 -hour time -point.  
• Any initiation of rescue therapies greater than 3 hours after randomization and up to 12 hours post- randomization should result in poor/none hemostatic efficacy.  
• Any administration of andexanet starting greater than 3 hours after randomization and up to 12 hours post -randomization should result in poor/none hemostatic efficacy.  
• Any surgical procedures specifically intended to treat the hematoma occurring 
between 3 hours after randomization and up to 12 hours post -randomization should 
result in poor/none hemostatic efficacy.  
Not Evaluable  • Insufficient information available to determine change from baseline in NIHSS, OR  
• Insufficient imaging information (i.e., missing or uninterpretable imaging scan) to determine change from baseline in volume, OR  
• Insufficient information available to determine whether patient received rescue therapy.  
• These cases will be further adjudicated to determine if they are non -evaluable from 
administrative reasons (e.g., scan not available for technical reason, transfer to 
another facility, or hematoma drainage not due to clinical deterioration) or clinic al 
reasons (scan not available because of patient deterioration).  Cases assessed as non -
evaluable for clinical reasons will be imputed as having poor/none hemostatic 
efficacy.  
Note :  This Appendix is intended only as a guide to Investigators and is not intended to be comprehensive.  Full 
details on the rating of hemostatic efficacy are provided in the Adjudication Charter.  
a Rescue therapies defined as any pro- coagulant replacement factor products (e.g., 3 - and 4 -factor prothrombin 
complex concentrates, activated PCCs, FEIBA®, recombinant fVIIa, plasma, FFP, whole blood), any systemic or 
local hemostatic therapies (except tranexamic acid), or the conduct of unplanned surgeries/procedures to treat the hematoma.  
Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022 Page 91 APPENDIX C.  GLASGOW COMA SCALE (GCS)  
Score  Criterion  
Eye Opening  
4 Open before stimulus  
3 After spoken or shouted request  
2 After fingertip stimulus  
1 No opening at any time, no interfering factor  
NT Closed by local factor  
Verbal Response  
5 Correctly gives name, place, and date  
4 Not orientated but communication coherently  
3 Intelligible single words  
2 Only moans/groans  
1 No audible response, nom interfering factor  
NT Factor interfering with communication  
Best Motor Response  
6 Obey 2 -part request  
5 Brings hand above clavicle to stimulus on head/neck  
4 Bends arm at elbow rapidly but features not predominantly abnormal  
3 Bends arm at elbow, features clearly predominantly abnormal 
2 Extends arm at elbow  
1 No movement in arms/legs, no interfering factor  
NT Paralyzed or other limiting factor  
NT = Not testable  
 
Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022 Page 92 APPENDIX D.  MODIFIED RANKIN SCALE (MRS)  
Score  Description  
0 No symptoms at all  
1 No significant disability despite symptoms; able to carry out all usual duties and activities  
2 Slight disability; unable to carry out all previous activities, but able to look after own affairs without 
assistance  
3 Moderate disability; requiring some help, but able to walk without assistance  
4 Moderately severe disability; unable to walk without assistance and unable to atten d to own bodily 
needs without assistance  
5 Severe disability; bedridden, incontinent, and requiring constant nursing care and attention  
6 Dead  
 
Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022 Page 93 APPENDIX E.  NATIONAL INSTITUTES OF HEALTH STROKE SCALE  
 

Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022 Page 94  
 

Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022 Page 95  
 

Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022 Page 96  

Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022 Page 97  
 

Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceu ticals, Inc.  
Alexion Confidential  01 December 2022 Page 98  
 

Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022 Page 99  
 

Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022 Page 100  
 
 

Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022 Page 101 APPENDIX F.  COVID- 19:  POTENTIAL RISKS AND MITIGATION MEASURES  
Risk Category  Summary of Data/ Rationale for Risk  Mitigation Strategy  
Potentially higher risk population 
for SARS ‑CoV‑2 infection  It is unknown how this may impact their risk for 
SARS‑CoV‑2 infection.  During the time that the COVID ‑19 pandemic is active, 
Alexion will recommend that sites in a position to  start the 
study and enroll participants follow national and institutional 
guidance regarding prevention of SARS‑CoV‑2 infection.  
Additionally, during that time period, it is expected that Investigators and their staff will take all possible precautions in order to minimize a participant’s potential exposure to 
SARS‑CoV‑2 infection.  Depending on the site, these precautions will consist of measures such as social distancing, 
temperature screening, enhanced cleaning, and use of 
personal protective equipment for participants, staff, and 
caregivers as necessary.  
Healthcare institution availability 
for non‑COVID -19-related 
activities  COVID‑19 pandemic may impact the workload of 
healthcare institutions globally and may reduce staff availability to perform non‑urgent activities and 
non-COVID‑19 related activities.  During the time that the COVID ‑19 pandemic is active, 
Alexion will not open study sites or enroll new participants at sites unless the sites have the resourcing and capabilities to implement the study per protocol.  
Data quality and integrity  Lack of availability of site personnel to perform study 
assessments and capture study specific data in a timely manner and to maintain adequate quality standards.  
Lack of availability of site personnel to ensur e adequate 
and continuous chain of custody, storage conditions, and monitoring for investigational product and biological samples.  
Inability of study monitors and quality personnel to conduct in- person visits to exercise adequate oversight 
of study executi on at investigational sites.  
Missing data (COVID ‑19 pandemic may impact study 
visit schedules and increase missed visits and/or 
participant study discontinuations inadvertently resulting 
in missing data [e.g., for protocol -specified procedures]).  During th e time that the COVID ‑19 pandemic is active, 
Alexion will only open study sites that report enough personnel capacity to sufficiently conduct clinical study‑related activities.  
During this timeframe, participants eligibility as well as site capacity will b e reviewed by the site Investigator and the 
study Medical Monitor prior to Screening. Each site is also evaluated for the capacity to perform remote monitoring visits and remote source data verification.  
During the time that the COVID‑19 pandemic is active , it will 
be important to capture specific information in the eCRF that explains the reason the data is missing (e.g., missed study visits or participant study discontinuations due to COVID‑19).  
COVID -19 = coronavirus disease 2019; eCRF  =electronic case report form; SARS ‑CoV‑2 = severe acute respiratory syndrome coronavirus  2. 
Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 102 APPENDIX G.  EXAMPLES OF PLANNED MINIMALLY INVASIVE SURGERIES/ 
PROCEDURES ALLOWED  
• Neurologic interventions (e.g., Burr hole, craniotomy) that are specifically indicated 
for a reason other than hematoma evacuation (e.g., intracranial pressure monitoring).  
Any procedure intended to drain a hematoma, or potentially having an effect on hematoma volume, is excluded.  
• Joint arthroscopy 
• Thoracentesis  
• Pericardial puncture/drainage  
• Embolization  
• Endoscopy with cauterization/embolization  
• Cystoscopy 
• Laparocentesis  
• Lumbar puncture 
• Colonoscopy 
• CT-guided abscess drainage 
• Joint arthrocentesis  
• Percutaneous biopsy  
 
Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 103 APPENDIX H.  DISSEMINATED INTRAVASCULAR COAGULATION SCORING 
ALGORITHM  
Laboratory Test  Result  Score  
Platelet Count  ≥ 100 x 109/L 0 
< 100 x 109/L 1 
< 50 x 109/L 2 
D-dimer, Fibrin Degradation Products  No increase  0 
Moderate increase  2 
Strong increase  3 
Prothrombin Time  < 3 seconds  0 
≥ 3 but <  6 seconds  1 
≥ 6 seconds  2 
Fibrinogen Level  ≥ 1 g/L  0 
< 1 g/L 1 
Source:  Levi 2009 [33]. 
Note :  Algorithm should only be used for patients with an underlying disorder known to be associated 
with overt disseminated intravascular coagulation (DIC).  A score of ≥ 5 is compatible with overt 
DIC.  
 
Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 104 APPENDIX I.  DEFINITIONS OF CARDIOGENIC SHOCK, SEVERE SEPSIS AND 
SEPTIC SHOCK  
Cardiogenic shock  is a cardiac disorder that results in both clinical and biochemical evidence of 
tissue hypoperfusion [ 34].  The definition of cardiogenic shock may be clinically determined and 
consists of the following:  SBP < 90 mmHg for at least 30 minutes, OR 
• Hemodynamic support required to maintain SBP ≥ 90 mm Hg, AND  
• End-organ hypoperfusion (e.g., urine output < 30 mL/h or cool extremities)  
Cardiogenic shock may also be optionally defined by hemodynamic criteria obtained through 
invasive hemodynamic monitoring:  
• Cardiac index ≤ 2.2 L/min/m2, AND 
• Pulmonary capil lary wedge pressure ≥ 15 mm Hg 
Severe sepsis is defined as sepsis plus sepsis -induced tissue hypoperfusion or organ dysfunction 
with any of the following thought to be due to the infection: 
• Sepsis-induced hypotension 
• Lactate above ULN  
• Urine output < 0.5 mL/kg/h  for more than two hours despite adequate fluid 
resuscitation  
• Acute lung injury with arterial oxygen partial pressure/fractional inspired oxygen 
PaO 2/FIO 2 < 250 mm Hg in the absence of pneumonia as infection source 
• Acute lung injury with PaO 2/FIO 2 < 200 mm Hg in the presence of pneumonia as 
infection source  
• Creatinine >  2 mg/dL (176.8 μmol/L) 
• Bilirubin >  4 mg/dL (34.2 μmol/L)  
• Platelet count <  100,000/μL 
• Coagulopathy (INR > 1.5) 
Sepsis -induced tissue hypoperfusion  is defined as infection -induced hypotension, elevated 
lactate, or oliguria.  
Sepsis -induced hypotension is defined as an SBP < 90 mm Hg, or mean arterial pressure <  70 
mmHg, or a SBP decrease > 40 mm Hg, or less than two standard deviations below normal for age in the absence of other causes of hypotension.  
Septic shock is defined as sepsis-induced hypotension (as defined above) persisting despite 
adequate fluid resuscitation  [35]. 
Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 105 APPENDIX J. DEFINITION OF FEMALE OF CHILDBEARING POTENTIAL  
All women of childbearing potential (including those who have had a tubal ligation) will have a 
urine or serum pregnancy test at screening.  If the pregnancy test is positive, andexanet should 
not be administered.  
All female patients are considered to be of childbearing potential unless they meet one of the 
following criteria:  
1. The patient has been post- menopausal (amenorrheic) for at least 1  year  
2. The patient had a surgical bilateral oophorectomy (with or without hysterectomy) more 
than 6 weeks prior to scr eening 
3. The patient had a hysterectomy  
4. The patient is ≥ 65 years of age 
Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 106 APPENDIX K.  GUIDANCE FOR SUBMISSION OF POTENTIAL THROMBOTIC 
EVENTS FOR ADJUDICATION 
Adjudication criteria for the diagnosis of TIAs, strokes, MIs, VTE, and arterial systemic 
embolism are provided b elow.  
TIA is defined as a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, with signs or symptoms lasting < 24 hours and no evidence of new 
infarct on neuroimaging if performed.  Investigators should consider submitting cases for 
adjudication if an event meets this definition.  
Stroke  is defined as an acute episode of neurological dysfunction consistent with a vascular 
cause.  A stroke will be considered to have occurred if there is a rapid onset of signs and/or 
symptoms of a new persistent neurological deficit consistent with an obstruction to cerebral 
blood flow with no apparent nonischemic cause (e.g., trauma, tumor, or infection).  Signs or 
symptoms must last at least 24 hours or, for symptom onset less than 24 hours, have 
neuroimaging evidence of new infarct.  Available neuroimaging studies will be considered to 
support the clinical impression and to determine if there is a demonstrable lesion compatible with 
an acute stroke.  For the diagnosis of stro ke, the following criteria must be fulfilled:  
• Rapid onset of a focal/global neurologic deficit with at least one of the following:  
change in level of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphagia/aphasia, hemianopia, amaurosis fugax, or other new neurological signs/symptoms consistent with stroke. 
• The duration of a focal/global neurologic deficit is at least 24 hours, OR the neurological deficit results in death, OR there is neuroimaging evidence of a new 
infarct.  
• There is no other readily identifiable non- stroke cause for the clinical presentation 
(e.g., brain tumor, trauma, infection, hypoglycemia, peripheral lesion). 
• Confirmation of the diagnosis by at least one of the following:  specialist evaluation, or brain imaging procedure (i.e., CT scan, MRI scan, cerebral vessel angiography). 
If the acute neurological signs represent a worsening of a previous (baseline) deficit, the new 
signs must have either persisted for more than  one week, or persisted for more than 24 hours and 
were accompanied by an appropriate new imaging finding. 
Investigators should consider submitting cases for adjudication as a possible stroke if they meet 
one or more of the above criteria, or have potential symptoms and/or conditions (e.g., delirium, 
mental status changes) that are not otherwise explainable by an alternative etiology.  
Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 107 Since the adjudication of hemostatic efficacy encompasses changes in clinical neurologic 
function and hematoma volume, these  findings will only be considered for TE adjudication if 
they clearly have an ischemic etiology.  
MI should be used when there is evidence of myocardial necrosis in a clinical setting consistent 
with acute myocardial ischemia.  Under these conditions any one of the following criteria meets the diagnosis of MI:  
• Detection of a rise and/or fall of cardiac biomarker values (preferably cardiac 
troponin [cTn]) with at least one value above the ULN and with at least one of the following:  
○ Symptoms of ischemia  
○ New or  presumed new significant ST- segment -T wave (ST- T) changes or new left 
bundle branch block 
○ Development of pathological Q waves in the ECG 
○ Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality  
○ Identification of an intraco ronary thrombus by angiography or autopsy 
• Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic ECG changes or new left bundle branch block (LBBB), but death occurred before biomarkers were obtained, or before cardiac biomarker values would be 
increased  
• Percutaneous coronary intervention related MI is arbitrarily defined by elevation of cTn values (> 5x ULN) in patients with normal baseline values or a rise of cTn values> 20% if the baseline values are elevated and are stable or falling.  In addition, 
either (i) symptoms suggestive of myocardial ischemia, (ii) new ischemic ECG changes, (iii) angiographic findings consistent with a procedural complication, or (iv) imaging demonstration of new loss of viable myocar dium or new regional wall 
motion abnormality are required.  
• Stent thrombosis associated with MI when detected by coronary angiography or autopsy in the setting of myocardial ischemia and with a rise and/or fall of cardiac biomarker values with at least one value above the ULN 
• Coronary artery bypass grafting related MI is arbitrarily defined by elevation of cardiac biomarker values (> 10x ULN) in patients with normal baseline cTn values.  In addition, either (i) new pathological Q waves or new LBBB, (ii) angiographic documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.  
Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 108 Investigators should consider submitting cases for adjudication as a possible MI if they meet one 
or more of the above criteria, or have potential symptoms and/or conditions (e.g., angina, 
ventricular tachyarrhythmia, cardiogenic shock, heart failure) that are not otherwise explainable 
by an alternative etiology.  All cases of unexplained sudden death should also be submitted for 
adjudication as a possible MI and/or PE.  
VTE is defined as a symptomatic DVT or PE confirmed by objective testing.  Criteria for the 
objective confirmation of DVT include: 
• A constant filling defect in two or more views on contrast venography in one or more 
proximal venous segments (iliac, common femoral, superficial femoral, popliteal)  
• New or previously undocumented non-compressibility of one or more venous segments on compression ultrasound 
• A clearly defined intraluminal filling defect on contrast enhanced CT 
Criteria for the objective confirmation of PE include:  
• An intraluminal filling defect on pulmonary angiography 
• Sudden contrast cut- off of one or more vessels more than 2.5 mm in diameter on a 
pulmonary angiogram 
• A high probability VQ scan (one or more segmental perfusion defects with corresponding normal ventilation) 
• An abnormal non-high VQ scan plus criteria for the diagnosis of DVT 
• An unequivocal, intra- arterial, un -enhancing filling defect in the central pulmonary 
vasculature (pulmonary trunk, main pulmonary arteries, anterior trunk, right and left interlobar and lobar arteries) on CT  
Investigators should consider submitting cases for adjudication as a possible VTE if they meet 
one or more of the above criteria, or have potential symptoms and/or conditions (e.g., lower 
extremity swelling, respiratory failure) that are not otherwise explainable by an alternate 
etiology.  All cases of unexplained sudden death should also be submitted for adjudication as a 
possible PE and/or MI. 
Arterial systemic embolism is defined as abrupt vascular insufficiency associated with clinical 
and other objective evidence of arterial occlusion in the absence of other likely mechanisms.  
Clinical signs and symptoms must be c onsistent with embolic arterial occlusion, and there must 
be clear evidence of abrupt occlusion of a systemic artery, with at least one type of supporting 
evidence, such as surgical report indicating evidence of arterial embolism, pathological 
specimens related to embolism removal, imaging evidence consistent with arterial embolism, or 
autopsy report.  Investigators should consider submitting potential systemic arterial embolism 
cases for adjudication if they meet this definition.  
Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 109 APPENDIX L.  EUROQOL- 5 DIMENSION (EQ -5D) QUESTIONNAIRE  
 
 

Protocol Amendment 2   ALXN2070 18 -513 (ANNEXA -I) 
Andexanet Alfa   Alexion Pharmaceuticals, Inc.  
Alexion Confidential  01 December 2022  Page 110  
  
